

University of Groningen

Evidence-b(i)ased psychiatry

de Vries, Ymkje Anna

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2018

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

de Vries, Y. A. (2018). *Evidence-b(i)ased psychiatry*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Bibliography

- [1] R C Kessler, P A Berglund, O Demler, R Jin, K R Merikangas, and E E Walters. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*, 62:593–603, 2005.
- [2] American Psychiatric Association. *Diagnostic and statistical manual of mental disorders. 4th ed., text revision.* 2000.
- [3] B W J H Penninx, W A Nolen, F Lamers, F G Zitman, J H Smit, and P Spinhoven et al. Two-year course of depressive and anxiety disorders: results from the Netherlands Study of Depression and Anxiety (NESDA). *J Affect Disord*, 133(1-2):76–85, 2011.
- [4] R C Kessler, W T Chiu, O Demler, and E E Walters. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*, 62:617–627, 2005.
- [5] R F Krueger. The structure of common mental disorders. *Arch Gen Psychiatry*, 56(10):921–926, 1999.
- [6] M M Fichter, N Quadflieg, U C Fischer, and G Kohlboeck. Twenty-five-year course and outcome in anxiety and depression in the Upper Bavarian Longitudinal Community Study. *Acta Psychiatr Scand*, 122(1):75–85, 2010.
- [7] T E Moffitt, H Harrington, A Caspi, J Kim-Cohen, D Goldberg, A M Gregory, and R Poulton. Depression and generalized anxiety disorder: cumulative and sequential comorbidity in a birth cohort followed prospectively to age 32 years. *Arch Gen Psychiatry*, 64(6):651–60, 2007.
- [8] E J Costello, S Mustillo, A Erkanli, G Keeler, and A Angold. Prevalence and development of psychiatric disorders in childhood and adolescence. *Arch Gen Psychiatry*, 60(8):837–44, 2003.
- [9] J Ormel, D Raven, F van Oort, Catharina A Hartman, S A Reijneveld, R Veenstra, Wilma A M Vollebergh, J Buitelaar, F C Verhulst, and A J Oldehinkel. Mental health in Dutch adolescents: a TRAILS report on prevalence, severity, age of onset, continuity and co-morbidity of DSM disorders. *Psychol Med*, 45(02):345–360, 2015.
- [10] R Gaspersz, F Lamers, J M Kent, A T F Beekman, J H Smit, A M van Hemert, R A Schoevers, and B W J H Penninx. Longitudinal predictive validity of the DSM-5 anxious distress specifier for clinical outcomes in a large cohort of patients with major depressive disorder. *J Clin Psychiatry*, 78(2):207–213, 2017.
- [11] A Qaseem, M J Barry, and D Kansagara. Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: a clinical practice guideline from the American College of Physicians. *Ann Intern Med*, 164:350–359, 2016.
- [12] B Bandelow, L Sher, R Bunevicius, E Hollander, S Kasper, J Zohar, and H-J Möller. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. *International Journal of Psychiatry in Clinical Practice*, 16(2):77–84, 2012.
- [13] National Institute for Health and Clinical Excellence. Generalised anxiety disorder and panic disorder in adults: management (CG113). Technical report, 2011.
- [14] National Institute for Health and Clinical Excellence. Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31). Technical report, 2005.
- [15] National Institute for Clinical Excellence. Post-traumatic stress disorder: management (CG26). Technical report, 2005.

-
- [16] National Institute for Health and Care Excellence. Social anxiety disorder: recognition, assessment and treatment (CG159). Technical report, 2013.
- [17] M E Franklin and E B Foa. Treatment of obsessive compulsive disorder. *Annu Rev Clin Psychol*, 7:229–243, 2011.
- [18] D F Gros, N P Allan, and D D Szafranski. Movement towards transdiagnostic psychotherapeutic practices for the affective disorders. *Evid Based Ment Health*, 19(3):1–4, 2016.
- [19] E H Turner, A M Matthews, E Linardatos, R A Tell, and R Rosenthal. Selective publication of antidepressant trials and its influence on apparent efficacy. *N Engl J Med*, 358(3):252–60, 2008.
- [20] A M Roest, P de Jonge, C D Williams, Y A de Vries, R A Schoevers, and E H Turner. Reporting bias in clinical trials investigating the efficacy of second-generation antidepressants in the treatment of anxiety disorders: a report of 2 meta-analyses. *JAMA Psychiatry*, 72(5):500 – 510, 2015.
- [21] M Huhn, M Tardy, L M Spineli, W Kissling, H Förstl, G Pitschel-Walz, C Leucht, M Samara, M Dold, J M Davis, and S Leucht. Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses. *JAMA Psychiatry*, 71(6):706, 2014.
- [22] F J Farach, L D Pruitt, J J Jun, Al B Jerud, L A Zoellner, and P P Roy-Byrne. Pharmacological treatment of anxiety disorders: Current treatments and future directions. *Journal of Anxiety Disorders*, 26(8):833–843, 2012.
- [23] J Wong, A Motulsky, T Eguale, D L Buckeridge, M Abrahamowicz, and R Tamblyn. Treatment indications for antidepressants prescribed in primary care in Quebec, Canada, 2006 - 2015. *JAMA*, 315(20):2230–2231, 2016.
- [24] T J Moore and D R Mattison. Adult utilization of psychiatric drugs and differences by sex, age, and race. *JAMA Intern Med*, 177(2):274 – 275, 2017.
- [25] G Verweij and M Houben-van Herten. Bevolkingstrends 2013: Depressiviteit en antidepressiva in Nederland. Technical report, Centraal Bureau voor de Statistiek, 2013.
- [26] L Cosgrove, S Krinsky, E E Wheeler, S M Peters, M Brodt, and A F Shaughnessy. Conflict of interest policies and industry relationships of guideline development group members: a cross-sectional study of clinical practice guidelines for depression. *Accountability in Research*, 24(2):99–115, 2016.
- [27] H Melander, J Ahlqvist-Rastad, G Meijer, and B Beermann. Evidence based medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. *BMJ*, 326:1–5, 2003.
- [28] J N Jureidini, L B McHenry, and P R Mansfield. Clinical trials and drug promotion: selective reporting of study 329. *Int J Risk Saf Med*, 20:73–81, 2008.
- [29] J N Jureidini, J D Amsterdam, and L B McHenry. The citalopram CIT-MD-18 pediatric depression trial: Deconstruction of medical ghostwriting, data mischaracterisation and academic malfeasance. *Int J Risk Saf Med*, 28(1):33–43, 2016.
- [30] R Keller, N D Ryan, M Strober, R G Klein, S P Kutcher, and B Birmaher et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. *J Am Acad Child Adolesc Psychiatry*, 40(7):762–772, 2001.
- [31] M Parsons. Paroxetine in adolescent major depression. *J Am Acad Child Adolesc Psychiatry*, 41(4):364, 2002.
- [32] J Jureidini and A Tonkin. Paroxetine in major depression. *J Am Acad Child Adolesc Psychiatry*, 42(5):514, 2003.
- [33] J Le Noury, J M Nardo, D Healy, J Jureidini, M Raven, C Tufanaru, and E Abi-Jaoude. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. *BMJ*, 351:h4320, 2015.
- [34] D Fanelli. Negative results are disappearing from most disciplines and countries. *Scientometrics*, 90(3):891–904, 2012.
- [35] E Driessen, S D Hollon, C L H Bockting, P Cuijpers, and E H Turner. Does publication bias inflate the apparent efficacy of psychological treatment for major depressive disorder? A systematic review and meta-analysis of US National Institutes of Health-funded trials. *PLOS ONE*, 10(9):e0137864, 2015.
- [36] T D Sterling. Publication decisions and their possible effects on inferences drawn from

- tests of significance—or vice versa. *Journal of the American Statistical Association*, 54(285):30, 1959.
- [37] S Hopewell, K Loudon, M J Clarke, A D Oxman, and K Dickersin. Publication bias in clinical trials due to statistical significance or direction of trial results. *Cochrane Database Syst Rev*, (1), 2009.
- [38] K Dwan, C Gamble, P R Williamson, and J J Kirkham. Systematic review of the empirical evidence of study publication bias and outcome reporting bias - an updated review. *PLOS ONE*, 8(7):e66844, 2013.
- [39] S Mathieu, I Boutron, D Moher, D G Altman, and P Ravaud. Comparison of registered and published primary outcomes in randomized controlled trials. *JAMA*, 302(9):977, 2009.
- [40] I Boutron, S Dutton, P Ravaud, and D G Altman. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. *JAMA*, 303(20):2058–64, 2010.
- [41] I Boutron, D G Altman, S Hopewell, F Vera-Badillo, I Tannock, and P Ravaud. Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial. *Journal of Clinical Oncology*, 32(36):4120–4126, 2014.
- [42] J-F Etter and J Stapleton. Citations to trials of nicotine replacement therapy were biased toward positive results and high-impact-factor journals. *J Clin Epidemiol*, 62:831–837, 2009.
- [43] M Callaham, R L Wears, and E Weber. Journal prestige, publication bias, and other characteristics associated with citation of published studies in peer-reviewed journals. *JAMA*, 287(21):2847–2850, 2002.
- [44] S A Greenberg. How citation distortions create unfounded authority: analysis of a citation network. *BMJ*, 339:b2680, 2009.
- [45] P Nieminen, G Rucker, J Miettunen, J Carpenter, and M Schumacher. Statistically significant papers in psychiatry were cited more often than others. *J Clin Epidemiol*, 60:939–946, 2007.
- [46] F Song, S Parekh, L Hooper, Y K Loke, J Ryder, A J Sutton, C Hing, C S Kwok, C Pang, and I Harvey. Dissemination and publication of research findings: An updated review of related biases. *Health Technology Assessment*, 14(8):1–220, 2010.
- [47] U Jonsson, I Alaie, T Parling, and F K Arnberg. Reporting of harms in randomized controlled trials of psychological interventions for mental and behavioral disorders: a review of current practice. *Contemp Clin Trials*, 38(1):1–8, 2014.
- [48] B Vaughan, M H Goldstein, M Alikakos, L J Cohen, and M J Serby. Frequency of reporting of adverse events in randomized controlled trials of psychotherapy vs. psychopharmacotherapy. *Compr Psychiatry*, 55(4):849–55, 2014.
- [49] M Linden and M-L Schermuly-Haupt. Definition, assessment and rate of psychotherapy side effects. *World Psychiatry*, 13(3):306–309, 2014.
- [50] D J Nutt and M Sharpe. Uncritical positive regard? Issues in the efficacy and safety of psychotherapy. *J Psychopharmacol*, 22(1):3–6, 2008.
- [51] M J Crawford, L Thana, L Farquharson, L Palmer, E Hancock, P Bassett, J Clarke, and G D Parry. Patient experience of negative effects of psychological treatment: results of a national survey. *Br J Psychiatry*, 208(3):260–265, 2016.
- [52] A Rozental, A Kottorp, J Boettcher, G Andersson, and P Carlbring. Negative effects of psychological treatments: An exploratory factor analysis of the Negative Effects Questionnaire for monitoring and reporting adverse and unwanted events. *PLOS ONE*, 11(6):e0157503, 2016.
- [53] P N Papanicolaou, R Churchill, K Wahlbeck, and J P A Ioannidis. Safety reporting in randomized trials of mental health interventions. *Am J Psychiatry*, 161(9):1692–7, 2004.
- [54] John P A Ioannidis and Joseph Lau. Completeness of safety reporting in randomized trials. *JAMA*, 285(4):437, jan 2001.
- [55] B Wieseler, N Wolfram, N McGauran, M F Kerekes, V Vervölgyi, P Kohlepp, M Kamphuis, and U Grouven. Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data. *PLOS Med*, 10(10):e1001526, 2013.

-
- [56] Y K Loke and S Derry. Reporting of adverse drug reactions in randomised controlled trials - a systematic survey. *BMC Clinical Pharmacology*, 1:3, 2001.
- [57] E Maund, B Tendal, A Hróbjartsson, K J Jorgensen, A Lundh, J Schroll, and P C Göttsche. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. *BMJ*, 348:g3510, 2014.
- [58] S Hughes, D Cohen, and R Jaggi. Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study. *BMJ Open*, 4(7):e005535, 2014.
- [59] J Undurraga and R J Baldessarini. Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. *Neuropsychopharmacology*, 37(4):851–864, 2012.
- [60] M J Taylor, S Sen, and Z Bhagwagar. Antidepressant response and the serotonin transporter gene-linked polymorphic region. *Biol Psychiatry*, 68(6):536–543, 2010.
- [61] S Porcelli, C Fabbri, and A Serretti. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. *Eur Neuropsychopharmacol*, 22(4):239–58, 2012.
- [62] J Flint and M R Munafó. Candidate and non-candidate genes in behavior genetics. *Curr Opin Neurobiol*, 23(1):57–61, 2013.
- [63] P F Sullivan. Spurious genetic associations. *Biol Psychiatry*, 61(10):1121–6, 2007.
- [64] J P Simmons, L D Nelson, and U Simonsohn. False-positive psychology: undisclosed flexibility in data collection and analysis allows presenting anything as significant. *Psychol Sci*, 22(11):1359–66, 2011.
- [65] J P A Ioannidis, R Tarone, and J K McLaughlin. The false-positive to false-negative ratio in epidemiologic studies. *Epidemiology*, 22(4):450–6, 2011.
- [66] R Uher, K E Tansey, M Rietschel, N Henigsberg, W Maier, and O Mors et al. Common genetic variation and antidepressant efficacy in major depressive disorder: A meta-analysis of three genome-wide pharmacogenetic studies. *Am J Psychiatry*, 170(2):207–217, 2013.
- [67] S Kapur, A G Phillips, and T R Insel. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? *Mol Psychiatry*, 17:1174–1179, 2012.
- [68] T Hahn, Andrew A Nierenberg, and S Whitfield-Gabrieli. Predictive analytics in mental health: applications, guidelines, challenges and perspectives. *Mol Psychiatry*, 22(1):37–43, 2016.
- [69] I Kirsch, B J Deacon, T B Huedo-Medina, A Scoboria, T J Moore, and B T Johnson. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. *PLOS Med*, 5(2):e45, 2008.
- [70] A Khan, R M Leventhal, S R F Khan, and W A Brown. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. *J Clin Psychopharmacol*, 22(1):40–45, 2002.
- [71] A Khan, A E Brodhead, R L Kolts, and W A Brown. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. *J Psychiatr Res*, 39(2):145–50, 2005.
- [72] J C Fournier, R J Derubeis, S D Hollon, S Dimidjian, J D Amsterdam, R C Shelton, and J Fawcett. Antidepressant drug effects and depression severity. *JAMA*, 303(1):47–53, 2010.
- [73] National Collaborating Centre for Mental Health. Depression: the NICE guideline on the treatment and management of depression in adults. Technical report, National Center for Clinical Excellence, 2010.
- [74] J Spijker, Claudi L H Bockting, J A C Meeuwissen, I M van Vliet, P M G Emmelkamp, M L M Hermens, and Anton J L M van Balkom. Multidisciplinaire richtlijn depressie (3e revisie, 2013). Technical report, Trimbos-instituut, Utrecht, 2013.
- [75] J Rabinowitz, N Werbeloff, F S Mandel, L Marangell, and S Kapur. Initial depression severity and response to antidepressants v . placebo: patient-level data analysis from 34 randomised controlled trials. *Br J Psychiatry*, 209(5):427–428, 2016.
- [76] R D Gibbons, K Hur, C H Brown, J M Davis, and J J Mann. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. *Arch Gen Psychiatry*, 69(6):572–9, 2012.

- [77] M A Sugarman, A M Loree, B B Baltes, E R Grekin, and I Kirsch. The efficacy of paroxetine and placebo in treating anxiety and depression: a meta-analysis of change on the Hamilton rating scales. *PLOS ONE*, 9(8):e106337, 2014.
- [78] D L Ackerman and S Greenland. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. *J Clin Psychopharmacol*, 22(3):309–17, 2002.
- [79] T A Furukawa, E S Weitz, S Tanaka, S D Hollon, S G Hofmann, and G Andersson et al. Initial severity of depression and efficacy of cognitive-behavioural therapy: individual-participant data meta-analysis of pill-placebo-controlled trials. *Br J Psychiatry*, 210(3):190–196, 2017.
- [80] E S Weitz, S D Hollon, J Twisk, A van Straten, M J H Huibers, and D David et al. Baseline depression severity as moderator of depression outcomes between cognitive behavioral therapy vs pharmacotherapy. *JAMA Psychiatry*, 72(11):1102 – 1109, 2015.
- [81] G E Simon and R H Perlis. Personalized medicine for depression: Can we match patients with treatments? *Am J Psychiatry*, 167(12):1445–1455, 2010.
- [82] R H Perlis. A clinical risk stratification tool for predicting treatment resistance in major depressive disorder. *Biol Psychiatry*, 74(1):7–14, 2013.
- [83] A M Chekroud, R J Zotti, Z Shehzad, R Gueorguieva, M K Johnson, M H Trivedi, T D Cannon, J H Krystal, and P R Corlett. Cross-trial prediction of treatment outcome in depression: a machine learning approach. *Lancet Psychiatry*, 3(3):243–250, 2016.
- [84] R J DeRubeis, Z D Cohen, N R Forand, J C Fournier, L A Gelfand, and L Lorenzo-Luaces. The Personalized Advantage Index: translating research on prediction into individualized treatment recommendations. A demonstration. *PLOS ONE*, 9(1):e83875, 2014.
- [85] M J H Huibers, Z D Cohen, L H J M Lemmens, A Arntz, F P M L Peeters, P Cuijpers, and R J DeRubeis. Predicting optimal outcomes in cognitive therapy or interpersonal psychotherapy for depressed individuals using the Personalized Advantage Index approach. *PLoS ONE*, 10(11):1–16, 2015.
- [86] American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. Technical report, 2010.
- [87] A Szegeedi, W T Jansen, A P P Van Willigenburg, E Van Der Meulen, H H Stassen, and M E Thase. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: A meta-analysis including 6562 patients. *J Clin Psychiatry*, 70(3):344–353, 2009.
- [88] E Jakubovski and M H Bloch. Prognostic subgroups for citalopram response in the STAR*D trial. *J Clin Psychiatry*, 75(7):738–747, 2014.
- [89] M Rynn, S Khalid-Khan, J F Garcia-Espana, B Etemad, and K Rickels. Early response and 8-week treatment outcome in GAD. *Depress Anxiety*, 23(8):461–465, 2006.
- [90] D S Baldwin, E Schweizer, Y Xu, and G Lyndon. Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR? *Eur Neuropsychopharmacol*, 22(2):137–142, 2012.
- [91] M Albus, Y Lecrubier, W Maier, R Buller, R Rosenberg, and H Hippus. Drug treatment of panic disorder: early response to treatment as a predictor of final outcome. *Acta Psychiatr Scand*, 82(5):359–365, 1990.
- [92] M H Pollack, M H Rapaport, R Fayyad, M W Otto, A A Nierenberg, and C M Clary. Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder. *J Psychiatr Res*, 36(4):229–236, 2002.
- [93] Mark H Pollack, Susan G Kornstein, Melissa E Spann, Paul Crits-Christoph, Joel Raskin, and James M Russell. Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. *J Psychiatr Res*, 42(14):1176–1184, 2008.
- [94] D S Baldwin, D J Stein, O T Dolberg, and B Bandelow. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. *Hum Psychopharmacol*, 24(4):269–275, 2009.
- [95] R Uher, O Mors, M Rietschel, A Rajewska-Rager, A Petrovic, A Zobel, N Henigsberg, J Mendlewicz, K J Aitchison, A Farmer, and P McGuffin. Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major

-
- depression: A secondary analysis of data from the genome-based therapeutic drugs for depression (GENDEP) study. *J Clin Psychiatry*, 72(11):1478–1484, 2011.
- [96] E I Fried and R M Nesse. Depression sum-scores don't add up: why analyzing specific depression symptoms is essential. *BMC Med*, 13(1):72, 2015.
- [97] E I Fried and R M Nesse. Depression is not a consistent syndrome: An investigation of unique symptom patterns in the STAR*D study. *J Affect Disord*, 172C:96–102, 2014.
- [98] H Sakurai, H Uchida, T Abe, S Nakajima, T Suzuki, B G Pollock, Y Sato, and M Mimura. Trajectories of individual symptoms in remitters versus non-remitters with depression. *J Affect Disord*, 151(2):506–513, 2013.
- [99] H Tokuoka, H Takahashi, A Ozeki, A Kuga, A Yoshikawa, T Tsuji, and M M Wohlreich. Trajectories of depression symptom improvement and associated predictor analysis: An analysis of duloxetine in double-blind placebo-controlled trials. *J Affect Disord*, 196:171–180, 2016.
- [100] K Funaki, S Nakajima, T Suzuki, M Mimura, and H Uchida. Early improvements in individual symptoms to predict later remission in major depressive disorder treated with mirtazapine. *J Clin Pharmacol*, 56(9):1111–1119, jan 2016.
- [101] D Eydling and M Lelgemann. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. *BMJ*, 341:c4737, 2010.
- [102] J P T Higgins and S Green, editors. *Cochrane Handbook for Systematic Reviews of Interventions*. The Cochrane Collaboration, 5 edition, 2011.
- [103] A-W Chan, A Hróbjartsson, M T Haahr, P C Gøtzsche, and D G Altman. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. *JAMA*, 291(20):2457–2465, 2004.
- [104] E H Turner, D Knoepfelmacher, and L Shapley. Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database. *PLOS Med*, 9(3):e1001189, 2012.
- [105] Erick H Turner. A taxpayer-funded clinical trials registry and results database. *PLOS Med*, 1(3):e60, dec 2004.
- [106] E H Turner. How to access and process FDA drug approval packages for use in research. *BMJ*, (347):f5992, 2013.
- [107] John P A Ioannidis. Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials? *Philosophy, Ethics, and Humanities in Medicine*, 3:14, 2008.
- [108] A Cipriani, T A Furukawa, G Salanti, J R Geddes, J P T Higgins, R Churchill, N Watanabe, A Nakagawa, I M Omori, H McGuire, M Tansella, and C Barbui. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. *Lancet*, 373(9665):746–58, 2009.
- [109] M Olfson and S C Marcus. National patterns in antidepressant medication treatment. *Arch Gen Psychiatry*, 66(8):848–856, 2009.
- [110] A J Baxter, K M Scott, T Vos, and H A Whiteford. Global prevalence of anxiety disorders: a systematic review and meta-regression. *Psychol Med*, 43(5):897–910, 2013.
- [111] J R T Davidson. First-line pharmacotherapy approaches for generalized anxiety disorder. *J Clin Psychiatry*, 70(suppl 2):25–31, 2009.
- [112] N M Batelaan, A J L M van Balkom, and D J Stein. Evidence-based pharmacotherapy of panic disorder: an update. *Int J Neuropsychopharmacol*, 15(3):403–415, 2011.
- [113] C Blanco, L B Bragdon, F R Schneier, and M R Liebowitz. The evidence-based pharmacotherapy of social anxiety disorder. *Int J Neuropsychopharmacol*, 16(1):235–49, 2013.
- [114] J C Ipser and D J Stein. Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). *Int J Neuropsychopharmacol*, 15(06):825–840, 2012.
- [115] N A Fineberg, A Brown, S Reghunandan, and I Pampaloni. Evidence-based pharmacotherapy of obsessive-compulsive disorder. *Int J Neuropsychopharmacol*, 15(08):1173–1191, 2012.
- [116] R B Hidalgo, L A Tupler, and J R T Davidson. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. *J Psychopharmacol*, 21(8):864–72, 2007.
- [117] F Kapczynski, J J S S dos Santos Souza, A A B C Batista Miralha da Cunha, and R R S

- Schmitt. Antidepressants for generalised anxiety disorder (GAD). *Cochrane Database Syst Rev*, 2:CD003592, 2003.
- [118] M W Otto, K S Tuby, R A Gould, R Y McLean, and Mark H Pollack. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. *Am J Psychiatry*, 158(12):1989–92, 2001.
- [119] C Andrisano, A Chiesa, and A Serretti. Newer antidepressants and panic disorder: a meta-analysis. *Int Clin Psychopharmacol*, 28(1):33–45, 2013.
- [120] D W Hedges, B L Brown, D A Shwalb, K Godfrey, and A M Larcher. The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials. *J Psychopharmacol*, 21(1):102–11, 2007.
- [121] G B De Menezes, E S F Coutinho, L F Fontenelle, P Vigne, I Figueira, and M Versiani. Second-generation antidepressants in social anxiety disorder: Meta-analysis of controlled clinical trials. *Psychopharmacology*, 215(1):1–11, 2011.
- [122] D J Stein, J C Ipser, and S Seedat. Pharmacotherapy for post traumatic stress disorder (PTSD). *Cochrane Database Syst Rev*, 1:CD002795, 2006.
- [123] G M Soomro, D G Altman, S Rajagopal, and M Oakley Browne. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). *Cochrane Database Syst Rev*, 1:CD001765, 2008.
- [124] M W Lipsey and D Wilson. *Practical Meta-analysis (Applied Social Research Methods)*. Sage Publications, 2001.
- [125] J P T Higgins and S G Thompson. Quantifying heterogeneity in a meta-analysis. *Statistics in Medicine*, 21(11):1539–1558, 2002.
- [126] K Rickels, M Rynn, M Iyengar, and D Duff. Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. *J Clin Psychiatry*, 67:41–47, 2006.
- [127] D J Stein, J Davidson, S Seedat, and K Beebe. Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studies. *Expert Opin Pharmacother*, 4(10):1829–1838, 2003.
- [128] J I Sheikh, P Lønborg, C M Clary, and R Fayyad. The efficacy of sertraline in panic disorder: combined results from two fixed-dose studies. *Int Clin Psychopharmacol*, 15(6):335–342, 2000.
- [129] P D Lønborg, R Wolkow, W T Smith, E DuBoff, D England, J Ferguson, M Rosenthal, and C Weise. Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. *Br J Psychiatry*, 173(1):54–60, 1998.
- [130] W K Goodman, A Bose, and Q Wang. Treatment of generalized anxiety disorder with escitalopram: Pooled results from double-blind, placebo-controlled trials. *J Affect Disord*, 87(2-3):161–167, 2005.
- [131] J R T Davidson, A Bose, A Korotzer, and H Zheng. Escitalopram in the treatment of generalized anxiety disorder: Double-blind, placebo controlled, flexible-dose study. *Depress Anxiety*, 19(4):234–240, 2004.
- [132] K Rickels, R Zaninelli, J McCaffery, K Bellew, M Iyengar, and D Sheehan. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. *Am J Psychiatry*, 160:749 – 756, 2003.
- [133] M H Pollack, R Zaninelli, A Goddard, J P McCafferty, K M Bellew, D B Burnham, and M K Iyengar. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. *J Clin Psychiatry*, 62(5):350–7, 2001.
- [134] H Koponen, C Allgulander, J Erickson, E Dunayevich, Y Pritchett, M J Detke, S G Ball, and J M Russell. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. *Prim Care Companion J Clin Psychiatry*, 9(2):100–7, 2007.
- [135] M Rynn, J Russell, J Erickson, M J Detke, S Ball, J Dinkel, K Rickels, and J Raskin. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. *Depress Anxiety*, 25(3):182–189, 2008.
- [136] J Hartford, S Kornstein, M Liebowitz, T Pigott, J Russell, M Detke, D Walker, S Ball, E Dunayevich, J Dinkel, and J Erickson. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. *Int Clin Psychopharmacol*, 22(3):167–74, 2007.

-
- [137] K Rickels, M H Pollack, D V Sheehan, and J T Haskins. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. *Am J Psychiatry*, 157(6):968–974, 2000.
- [138] J R T Davidson, R L DuPont, D Hedges, and J T Haskins. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. *J Clin Psychiatry*, 60(8):528–535, 1999.
- [139] J C Ballenger, D E Wheadon, M Steiner, W Bushnell, and I P Gergel. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. *Am J Psychiatry*, 155(1):36–42, 1998.
- [140] S Oehrberg, P E Christiansen, K Behnke, A L Borup, B Severin, J Soegaard, H Calberg, R Judge, J K Ohrstrom, and P M Manniche. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. *Br J Psychiatry*, 167:374–379, 1995.
- [141] Y Lecrubier, A Bakker, G Dunbar, and R Judge. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. *Acta Psychiatr Scand*, 95(2):145–52, 1997.
- [142] D V Sheehan, D B Burnham, M K Iyengar, and P Perera. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. *J Clin Psychiatry*, 66(1):34–40, 2005.
- [143] R B Pohl, R M Wolkow, and C M Clary. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. *Am J Psychiatry*, 155(9):1189–95, 1998.
- [144] M H Pollack, M W Otto, J J Worthington, G G Manfro, and R Wolkow. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. *Arch Gen Psychiatry*, 55(11):1010–1016, 1998.
- [145] M H Pollack, U Lepola, H Koponen, N M Simon, J J Worthington, G Emilien, E Tzanis, E Salinas, T Whitaker, and B Gao. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. *Depress Anxiety*, 24(1):1–14, 2007.
- [146] M Pollack, R Mangano, R Entsua, E Tzanis, N M Simon, and Y Zhang. A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. *Psychopharmacology*, 194(2):233–42, 2007.
- [147] M R Liebowitz, G Asnis, R Mangano, and E Tzanis. A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder. *J Clin Psychiatry*, 70(4):550–561, 2009.
- [148] J Bradwejn, A Ahokas, D J Stein, E Salinas, G Emilien, and T Whitaker. Venlafaxine extended-release capsules in panic disorder: Flexible-dose, double-blind, placebo-controlled study. *Br J Psychiatry*, 187(10):352–359, 2005.
- [149] J Davidson, J Yaryura-Tobias, R DuPont, L Stallings, L M Barbato, R G van der Hoop, and D Li. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. *J Clin Psychopharmacol*, 24(2):118–125, 2004.
- [150] H G M Westenberg, D J Stein, H Yang, D Li, and L M Barbato. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. *J Clin Psychopharmacol*, 24(1):49–55, 2004.
- [151] D Baldwin, J Bobes, D J Stein, I Scharwachter, and M Faure. Paroxetine in social phobia/social anxiety disorder: randomised, double-blind, placebo-controlled study. *Br J Psychiatry*, 175(2):120–126, 1999.
- [152] M B Stein, M R Liebowitz, R B Lydiard, C D Pitts, W Bushnell, and I Gergel. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. *JAMA*, 280(8):708–713, 1998.
- [153] M R Liebowitz, M B Stein, M Tancer, D Carpenter, R Oakes, and C D Pitts. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. *J Clin Psychiatry*, 63:66 – 74, 2002.
- [154] U Lepola, B Bergholdt, J St Lambert, K L Davy, and L Ruggiero. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. *J Clin Psychiatry*, 65(2):222–9, 2004.
- [155] M R Liebowitz, N A DeMartinis, K Weihs, P D Londborg, W T Smith, H Chung, R Fayyad, and C M Clary. Efficacy of sertraline in severe generalized social anxiety disorder.

- der: results of a double-blind, placebo-controlled study. *J Clin Psychiatry*, 64(7):785–92, 2003.
- [156] M A Van Ameringen, R M Lane, J R Walker, R C Bowen, P R Chokka, E M Goldner, D G Johnston, Y J Lavallee, S Nandy, J C Pecknold, V Hadrava, and R P Swinson. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. *Am J Psychiatry*, 158(2):275–281, 2001.
- [157] S Blomhoff, T T Haug, K Hellström, I Holme, M Humble, H P Madsbu, and J E Wold. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. *Br J Psychiatry*, 179(1):23–30, 2001.
- [158] M R Liebowitz, R M Mangano, J Bradwejn, and G Asnis. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. *J Clin Psychiatry*, 66(2):238–247, 2005.
- [159] K Rickels, R Mangano, and A Khan. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. *J Clin Psychopharmacol*, 24(5):488–496, 2004.
- [160] M J Friedman, C R Marmar, D G Baker, C S Sikes, and G M Farfel. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. *J Clin Psychiatry*, 68(5):711–720, 2008.
- [161] J R Davidson, B O Rothbaum, B A van der Kolk, C R Sikes, and G M Farfel. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. *Arch Gen Psychiatry*, 58(5):485–92, 2001.
- [162] K Brady, T Pearlstein, G M Asnis, D Baker, B Rothbaum, C R Sikes, and G M Farfel. Efficacy and safety of sertraline treatment of posttraumatic stress disorder. *JAMA*, 283(14):1837, 2000.
- [163] R D Marshall, K L Beebe, M Oldham, and R Zaninelli. Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. *Am J Psychiatry*, 158(12):1982–1988, 2001.
- [164] P Tucker, R Zaninelli, R Yehuda, L Ruggiero, K Dillingham, and C D Pitts. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. *J Clin Psychiatry*, 62(11):860–868, 2001.
- [165] G D Tollefson, A H Rampey, J H Potvin, M A Jenike, A J Rush, R A Dominguez, L M Koran, M K Shear, W Goodman, and L A Genduso. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. *Arch Gen Psychiatry*, 51(7):559–567, 1994.
- [166] S A Montgomery, A McIntyre, M Osterheider, P Sarteschi, W Zitterl, J Zohar, M Birkett, and A J Wood. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. *Eur Neuropsychopharmacol*, 3(2):143–52, 1993.
- [167] W K Goodman, M J Kozak, M Liebowitz, and K L White. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. *Int Clin Psychopharmacol*, 11(1):21–9, 1996.
- [168] E Hollander, L M Koran, W K Goodman, J H Greist, P T Ninan, H Yang, D Li, and L M Barbato. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. *J Clin Psychiatry*, 64(6):640–7, 2003.
- [169] E Hollander, A Allen, M Steiner, D E Wheadon, R Oakes, and D B Burnham. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. *J Clin Psychiatry*, 64(9):1113–1121, 2003.
- [170] J Zohar and R Judge. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. *Br J Psychiatry*, 169(4):468–474, 1996.
- [171] G Chouinard, W Goodman, J Greist, M Jenike, S Rasmussen, K White, E Hackett, M Gaffney, and P A Bick. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. *Psychopharmacol Bull*, 26(3):279–284, 1990.
- [172] J Greist, G Chouinard, E DuBoff, A Halaris, S W Kim, L Koran, M Liebowitz, R B Lydiard, S Rasmussen, and K White. Double-blind parallel comparison of three dosages

-
- of sertraline and placebo in outpatients with obsessive-compulsive disorder. *Arch Gen Psychiatry*, 52(4):289–95, 1995.
- [173] M H Kronig, J Apter, G Asnis, A Bystritsky, G Curtis, J Ferguson, R Landbloom, D Munjack, R Riesenber, D Robinson, P Roy-Byrne, K Phillips, and I J Du Pont. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. *J Clin Psychopharmacol*, 19(2):172–6, 1999.
- [174] G I Spielmans, T L Biehn, and D L Sawrey. A case study of salami slicing: pooled analyses of duloxetine for depression. *Psychother Psychosom*, 79(2):97–106, 2010.
- [175] K J Thaler, L C Morgan, M Van Noord, D E Jonas, M S McDonagh, K Peterson, A Glechner, and G Gartlehner. A case study of pooled-studies publications indicated potential for both valuable information and bias. *J Clin Epidemiol*, 66(10):1082–1092, 2013.
- [176] Erick H Turner. Publication bias, with a focus on psychiatry: Causes and solutions. *CNS Drugs*, 27:457–468, 2013.
- [177] P Cuijpers, F Smit, E Bohlmeijer, S D Hollon, and G Andersson. Efficacy of cognitive-behavioural therapy and other psychological treatments for adult depression: meta-analytic study of publication bias. *Br J Psychiatry*, 196(3):173–8, 2010.
- [178] A Yavchitz, I Boutron, A Bafeta, I Marroun, P Charles, J Mantz, and P Ravaud. Misrepresentation of randomized controlled trials in press releases and news coverage: a cohort study. *PLOS Med*, 9(9):e1001308, 2012.
- [179] S N Goodman. Toward evidence-based medical statistics. 2: The Bayes factor. *Ann Intern Med*, 130(12):1005–1013, 1999.
- [180] P Lockhart and B Guthrie. Trends in primary care antidepressant prescribing 1995 – 2007: a longitudinal population database analysis. *Br J Gen Pract*, 61(590):565–572, 2011.
- [181] R Mojtabei and M Olfson. National trends in long-term use of antidepressant medications: results from the U.S. National Health and Nutrition Examination Survey. *J Clin Psychiatry*, 75(2):169–77, 2014.
- [182] N McGauran, B Wieseler, J Kreis, Y-B Schüler, H Kölsch, and T Kaiser. Reporting bias in medical research - a narrative review. *Trials*, 11:37, 2010.
- [183] J P A Ioannidis, M R Munafò, P Fusar-Poli, B A Nosek, and S P David. Publication and other reporting biases in cognitive sciences: detection, prevalence, and prevention. *Trends Cogn Sci*, 18(5):235 – 241, 2014.
- [184] G B Emerson, W J Warme, F M Wolf, J D Heckman, R A Brand, and S S Leopold. Testing for the presence of positive-outcome bias in peer review: a randomized controlled trial. *JAMA Intern Med*, 170(21):1934–1939, 2010.
- [185] A P Prayle, M N Hurley, and A R Smyth. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. *BMJ*, 344(1):d7373, 2012.
- [186] K Dwan, D G Altman, M Clarke, C Gamble, J P T Higgins, J A C Sterne, P R Williamson, and J J Kirkham. Evidence for the selective reporting of analyses and discrepancies in clinical trials: a systematic review of cohort studies of clinical trials. *PLOS Med*, 11(6):e1001666, 2014.
- [187] B Bandelow, M Reitt, C Röver, S Michaelis, Y Görlich, and D Wedekind. Efficacy of treatments for anxiety disorders: a meta-analysis. *Int Clin Psychopharmacol*, 30(4):183–192, 2015.
- [188] H Vartiainen and E Leinonen. Double-blind study of mirtazapine and placebo in hospitalized patients with major depression. *Eur Neuropsychopharmacol*, 4(2):145–150, 1994.
- [189] R N Golden, C B Nemeroff, P McSorley, C D Pitts, and E M Dubé. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. *J Clin Psychiatry*, 63(7):577–84, 2002.
- [190] T A Hammad, T P Laughren, and J Racoosin. Suicidality in pediatric patients treated with antidepressant drugs. *Arch Gen Psychiatry*, 63:332–339, 2006.
- [191] M Stone, T P Laughren, M L Jones, M Levenson, P C Holland, A Hughes, T A Hammad, R Temple, and G Rochester. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. *BMJ*, 339:b2880, 2009.
- [192] T Sharma, L S Guski, N Freund, and P C Göttsche. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. *BMJ*, 352:i65, 2016.

- [193] Y Molero, P Lichtenstein, J Zetterqvist, C H Gumpert, and S Fazel. Selective serotonin reuptake inhibitors and violent crime: a cohort study. *PLOS Med*, 12(9):e1001875, 2015.
- [194] T J Moore, J Glenmullen, and C D Furberg. Prescription drugs associated with reports of violence towards others. *PLOS ONE*, 5(12):e15337, 2010.
- [195] D Healy, A Herxheimer, and D B Menkes. Antidepressants and violence: problems at the interface of medicine and law. *PLOS Med*, 3(9):e372, 2006.
- [196] P Saini, Yoon K Loke, Carrol Gamble, Douglas G Altman, Paula R Williamson, and Jamie J Kirkham. Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. *BMJ*, 349:g6501, 2014.
- [197] D M Hartung, D A Zarin, J-M Guise, M McDonagh, R Paynter, and M Helfand. Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications. *Ann Intern Med*, 160(7):477–483, 2014.
- [198] E Tang, P Ravaud, C Riveros, E Perrodeau, and A Dechartres. Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles. *BMC Med*, 13:189, 2015.
- [199] C Riveros, A Dechartres, E Perrodeau, R Haneef, I Boutron, and P Ravaud. Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals. *PLOS Med*, 10(12):e1001566, 2013.
- [200] J B Schroll, E Maund, and P C Gøtzsche. Challenges in coding adverse events in clinical trials: a systematic review. *PLOS ONE*, 7(7):e41174, 2012.
- [201] A C Plint, D Moher, A Morrison, K Schulz, D G Altman, C Hill, and I Gaboury. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. *Med J Aust*, 185(5):263–267, 2006.
- [202] J P A Ioannidis, S J W Evans, P C Gøtzsche, R T O’Neill, D G Altman, K Schulz, and D Moher. Better reporting of harms in randomized trials: an extension of the CONSORT statement. *Ann Intern Med*, 141:781–788, 2004.
- [203] B Hart, A Lundh, and L Bero. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. *BMJ*, 344:d7202, 2012.
- [204] K Rising, P Bacchetti, and L Bero. Reporting bias in drug trials submitted to the Food and Drug Administration: Review of publication and presentation. *PLOS Med*, 5(11):1561–1570, 2008.
- [205] Lilly press release, <https://web.archive.org/web/20080202133358/http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=287919>, 2008.
- [206] S M Miller, G J Naylor, M Murtagh, and G Winslow. A double-blind comparison of paroxetine and placebo in the treatment of depressed patients in a psychiatric outpatient clinic. *Acta Psychiatr Scand*, supp. 350:143–144, 1989.
- [207] G I Spielmans and P I Parry. From evidence-based medicine to marketing-based medicine: evidence from internal industry documents. *J Bioeth Inq*, 7(1):13–29, 2010.
- [208] R Smith. Medical journals are an extension of the marketing arm of pharmaceutical companies. *PLOS Med*, 2(5):e138, 2005.
- [209] The PLoS Medicine Editors. Ghostwriting: the dirty little secret of medical publishing that just got bigger. *PLOS Med*, 6(9):e1000156, 2009.
- [210] S Sisondo. Ghosts in the machine: publication planning in the medical sciences. *Soc Stud Sci*, 39(2):171–198, 2009.
- [211] S Ebrahim, S Bance, A Athale, C Malachowski, and J P A Ioannidis. Meta-analyses with industry involvement are massively published and report no caveats for antidepressants. *J Clin Epidemiol*, 70:155–163, 2015.
- [212] E C Settle, S M Stahl, S R Batey, J A Johnston, and J A Ascher. Safety profile of sustained-release bupropion in depression: Results of three clinical trials. *Clin Ther*, 21(3):454–463, 1999.
- [213] A G Pedersen. Citalopram and suicidality in adult major depression and anxiety disorders. *Nord J Psychiatry*, 60(5):392–9, 2006.
- [214] R K Bailey, C H Mallinckrodt, M M Wohlreich, J G Watkin, and J M Plewes. Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy. *J Natl Med Assoc*, 98(3):437–447, 2006.
- [215] P Bech, D K Kajdasz, and V Porsdal. Dose-response relationship of duloxetine in placebo-

-
- controlled clinical trials in patients with major depressive disorder. *Psychopharmacology*, 188(3):273–280, 2006.
- [216] S Brecht, D Kajdasz, S Ball, and M E Thase. Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder. *Int Clin Psychopharmacol*, 23(6):317–24, 2008.
- [217] S Brunton, F Wang, S B Edwards, A S Crucitti, M J Ossanna, D J Walker, and M J Robinson. Profile of adverse events with duloxetine treatment: A pooled analysis of placebo-controlled studies. *Drug Saf*, 33(5):393–407, 2010.
- [218] J Cookson, I Gilaberte, D Desai, and D K Kajdasz. Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat. *Int Clin Psychopharmacol*, 21(5):267–73, 2006.
- [219] P L Delgado, S K Brannan, C H Mallinckrodt, P V Tran, R K McNamara, F Wang, J G Watkin, and M J Detke. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. *J Clin Psychiatry*, 66(6):686–692, 2005.
- [220] S Dodd, M Berk, K Kelen, Q Zhang, E Eriksson, W Deberdt, and J C Nelson. Application of the Gradient Boosted method in randomised clinical trials: Participant variables that contribute to depression treatment efficacy of duloxetine, SSRIs or placebo. *J Affect Disord*, 168:284–293, 2014.
- [221] D L Dunner, D J Goldstein, C Mallinckrodt, Y Lu, and M J Detke. Duloxetine in treatment of anxiety symptoms associated with depression. *Depress Anxiety*, 18(2):53–61, 2003.
- [222] David L Dunner, Deborah N D’Souza, Daniel K Kajdasz, Michael J Detke, and James M Russell. Is treatment-associated hypomania rare with duloxetine: Secondary analysis of controlled trials in non-bipolar depression. *J Affect Disord*, 87(1):115–119, 2005.
- [223] D A Fishbain, M J Detke, J Wernicke, A S Chappell, and D K Kajdasz. The relationship between antidepressant and analgesic responses: findings from six placebo-controlled trials assessing the efficacy of duloxetine in patients with major depressive disorder. *Curr Med Res Opin*, 24(11):3105–3115, 2008.
- [224] J Greist, R K McNamara, C H Mallinckrodt, J N Rayamajhi, and J Raskin. Incidence and duration of antidepressant-induced nausea: Duloxetine compared with paroxetine and fluoxetine. *Clin Ther*, 26(9):1446–1455, 2004.
- [225] R Gueorguieva, C Mallinckrodt, and J H Krystal. Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses. *Arch Gen Psychiatry*, 68(12):1227–37, 2011.
- [226] E Harada, A Schacht, T Koyama, L B Marangell, T Tsuji, and R Escobar. Efficacy comparison of duloxetine and SSRIs at doses approved in Japan. *Neuropsychiatr Dis Treat*, 11:115–123, 2015.
- [227] J I Hudson, M M Wohlreich, D K Kajdasz, C H Mallinckrodt, J G Watkin, and O V Martynov. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. *Hum Psychopharmacol*, 20(5):327–341, 2005.
- [228] S G Kornstein, M M Wohlreich, C H Mallinckrodt, J G Watkin, and D E Stewart. Duloxetine efficacy for major depressive disorder in male vs. female patients: Data from 7 randomized, double-blind, placebo-controlled trials. *J Clin Psychiatry*, 67(5):761–770, 2006.
- [229] R Lewis-Fernandez, C Blanco, C H Mallinckrodt, M M Wohlreich, J G Watkin, and J M Plewes. Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy in U.S. Hispanic and majority Caucasian patients. *J Clin Psychiatry*, 67(9):1379–1390, 2006.
- [230] C H Mallinckrodt, D J Goldstein, M J Detke, Y Lu, J G Watkin, and P V Tran. Duloxetine: a new treatment for the emotional and physical symptoms of depression. *Prim Care Companion J Clin Psychiatry*, 5(1):19–28, 2003.
- [231] C H Mallinckrodt, J Raskin, M M Wohlreich, J G Watkin, and M J Detke. The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials. *BMC Psychiatry*, 4:26, 2004.
- [232] C H Mallinckrodt, J G Watkin, C Liu, M M Wohlreich, and J Raskin. Duloxetine in the

- treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features. *BMC Psychiatry*, 5:1, 2005.
- [233] C H Mallinckrodt, A Prakash, A C Andorn, J G Watkin, and M M Wohlreich. Duloxetine for the treatment of major depressive disorder: A closer look at efficacy and safety data across the approved dose range. *J Psychiatr Res*, 40:337–348, 2006.
- [234] C H Mallinckrodt, A Prakash, J P Houston, R Swindle, M J Detke, and M Fava. Differential antidepressant symptom efficacy: Placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). *Neuropsychobiology*, 56:73–85, 2008.
- [235] J C Nelson, M M Wohlreich, C H Mallinckrodt, M J Detke, J G Watkin, and J S Kennedy. Duloxetine for the treatment of major depressive disorder in older patients. *Am J Geriatr Psychiatry*, 13(3):227–35, 2005.
- [236] J C Nelson, Y L Pritchett, O Martynov, J Y Yu, C H Mallinckrodt, and M J Detke. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. *Prim Care Companion J Clin Psychiatry*, 8(4):212–9, 2006.
- [237] J C Nelson. Anxiety does not predict response to duloxetine in major depression: Results of a pooled analysis of individual patient data from 11 placebo-controlled trials. *Depress Anxiety*, 27(1):12–18, 2010.
- [238] J C Nelson. Effects of baseline depression severity on remission rates with duloxetine and placebo in anxious and nonanxious patients with major depression. *J Clin Psychopharmacol*, 31(5):682–4, 2011.
- [239] J C Nelson, Q Zhang, K Kelin, E Eriksson, W Deberdt, and M Berk. Baseline patient characteristics associated with placebo remission and their impact on remission with duloxetine and selected SSRI antidepressants. *Curr Med Res Opin*, 29(7):827–833, 2013.
- [240] C B Nemeroff, A F Schatzberg, D J Goldstein, M J Detke, C Mallinckrodt, Y L Pritchett, and P V Tran. Duloxetine for the treatment of major depressive disorder. *Psychopharmacol Bull*, 36(4):106–32, 2002.
- [241] D G Perahia, D K Kajdasz, D Desai, and P M Haddad. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. *J Affect Disord*, 89(1-3):207–212, 2005.
- [242] D G S Perahia, D K Kajdasz, M G Royer, D J Walker, and J Raskin. Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristics. *Int Clin Psychopharmacol*, 21(5):285–95, 2006.
- [243] Y L Pritchett, M D Marciniak, P K Corey-Lisle, R A Berzon, D Desai, and M J Detke. Use of effect size to determine optimal dose of duloxetine in major depressive disorder. *J Psychiatr Res*, 41:311–318, 2007.
- [244] A Schacht, P Gorwood, P Boyce, A Schaffer, and H Picard. Depression symptom clusters and their predictive value for treatment outcomes: results from an individual patient data meta-analysis of duloxetine trials. *J Psychiatr Res*, 53(1):54–61, 2014.
- [245] R C Shelton, A C Andorn, C H Mallinckrodt, M M Wohlreich, J Raskin, J G Watkin, and Michael J Detke. Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression. *Int Clin Psychopharmacol*, 22:348–355, 2007.
- [246] D E Stewart, M M Wohlreich, C H Mallinckrodt, J G Watkin, and S G Kornstein. Duloxetine in the treatment of major depressive disorder: Comparisons of safety and tolerability in male and female patients. *J Affect Disord*, 94(1-3):183–189, 2006.
- [247] M E Thase, P V Tran, C Wiltse, B A Pangallo, C Mallinckrodt, and M J Detke. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. *J Clin Psychopharmacol*, 25(2):132–40, 2005.
- [248] M E Thase, Y L Pritchett, M J Ossanna, R W Swindle, J Xu, and M J Detke. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. *J Clin Psychopharmacol*, 27(6):672–6, 2007.
- [249] L Viktrup, B A Pangallo, M J Detke, and N R Zinner. Urinary side effects of duloxetine in the treatment of depression and stress urinary incontinence. *Prim Care Companion J Clin Psychiatry*, 6(2):65–73, 2004.
- [250] J Wernicke, A Lledo, J Raskin, D K Kajdasz, and F Wang. An evaluation of the cardiovascular safety profile of duloxetine. *Drug Saf*, 30(5):437–455, 2007.
- [251] T N Wise, D G S Perahia, B A Pangallo, W G Losin, and C G Wiltse. Effects of the

-
- antidepressant duloxetine on body weight: analyses of 10 clinical studies. *Prim Care Companion J Clin Psychiatry*, 8(5):269–78, 2006.
- [252] D S Baldwin, E H Reines, C Guiton, and E Weiller. Escitalopram therapy for major depression and anxiety disorders. *Ann Pharmacother*, 41(10):1583–1592, 2007.
- [253] B Bandelow, H F Andersen, and O T Dolberg. Escitalopram in the treatment of anxiety symptoms associated with depression. *Depress Anxiety*, 24:53–61, 2007.
- [254] K Demyttenaere, H F Andersen, and E H Reines. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder. *Int Clin Psychopharmacol*, 23(5):276–286, 2008.
- [255] K Demyttenaere, E H Reines, S L Lönn, and M Lader. Satisfaction with medication is correlated with outcome but not persistence in patients treated with placebo, escitalopram, or serotonin-norepinephrine reuptake inhibitors: a post hoc analysis. *The primary care companion for CNS disorders*, 13(4), 2011.
- [256] J M Gorman, A Korotzer, and G Su. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. *CNS Spectrums*, 7(4 suppl 1):40–44, 2002.
- [257] S H Kennedy, H F Andersen, and M E Thase. Escitalopram in the treatment of major depressive disorder: A meta-analysis. *Curr Med Res Opin*, 25(1):161–175, 2009.
- [258] C D Kilts, A G Wade, H F Andersen, and T E Schlaepfer. Baseline severity of depression predicts antidepressant drug response relative to escitalopram. *Expert Opin Pharmacother*, 10(6):927–936, 2009.
- [259] M Lader, H F Andersen, and T Bækdal. The effect of escitalopram on sleep problems in depressed patients. *Hum Psychopharmacol*, 20(5):349–354, 2005.
- [260] R W Lam and H F Andersen. The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: An extended analysis. *Pharmacopsychiatry*, 39(5):180–184, 2006.
- [261] P M Llorca, J M Azorin, N Despiegel, and P Verpillat. Efficacy of escitalopram in patients with severe depression: A pooled analysis. *Int J Clin Pract*, 59(3):268–275, 2005.
- [262] G I Papakostas and K Larsen. Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram. *Eur Arch Psychiatry Clin Neurosci*, 261:147–156, 2011.
- [263] A G Pedersen. Escitalopram and suicidality in adult depression and anxiety. *Int Clin Psychopharmacol*, 20:139–143, 2005.
- [264] Dan J Stein, David S Baldwin, Ornah T Dolberg, Nicolas Despiegel, and Borwin Bandelow. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. *J Clin Psychiatry*, 67(11):1741–6, nov 2006.
- [265] D J Stein and A G Lopez. Effects of escitalopram on sleep problems in patients with major depression or generalized anxiety disorder. *Adv Ther*, 28(11):1021–1037, 2011.
- [266] A Wade and H Friis Andersen. The onset of effect for escitalopram and its relevance for the clinical management of depression. *Curr Med Res Opin*, 22(11):2101–2110, 2006.
- [267] P Bech. Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. *Int J Neuropsychopharmacol*, 4:337–345, 2001.
- [268] J Fawcett and R L Barbin. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. *J Clin Psychiatry*, 59(3):123–127, 1998.
- [269] S Stahl, M Zivkov, P E Reimtz, J Panagides, and W Hoff. Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. *Acta Psychiatr Scand*, 96(suppl 391):22–30, 1997.
- [270] D J Carpenter, R Fong, J E Kraus, J T Davies, C Moore, and M E Thase. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: A complete set of randomized placebo-controlled trials. *J Clin Psychiatry*, 72(11):1503–1514, 2011.
- [271] G C Dunbar, J B Cohn, L F Fabre, J P Feighner, R R Fieve, J Mendels, and R K Shrivastava. A comparison of paroxetine, imipramine and placebo in depressed out-patients. *Br J Psychiatry*, 159:394–8, 1991.

- [272] J P Feighner. A double-blind comparison of paroxetine, imipramine and placebo in depressed outpatients. *Int Clin Psychopharmacol*, 6 Suppl 4(suppl 4):31–35, 1992.
- [273] J P Feighner, J B Cohn, L F Fabre, R R Fieve, J Mendels, R K Shrivastava, and G C Dunbar. A study comparing paroxetine placebo and imipramine in depressed patients. *J Affect Disord*, 28(2):71–9, 1993.
- [274] J E Kraus, J P Horrigan, D J Carpenter, R Fong, P S Barrett, and J T Davies. Clinical features of patients with treatment-emergent suicidal behavior following initiation of paroxetine therapy. *J Affect Disord*, 120:40–47, 2010.
- [275] S A Montgomery. The advantages of paroxetine in different subgroups of depression. *Int Clin Psychopharmacol*, 6(suppl 4):91–100, 1992.
- [276] D L Dunner, A Lipschitz, C D Pitts, and J T Davies. Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials. *Clin Ther*, 27(12):1901–11, 2005.
- [277] C Berti, D P Doogan, N R Scott, and T G Dinan. Sertraline in the treatment of depressive disorders with associated anxiety. *J Serotonin Res*, 3:151–170, 1995.
- [278] C Fisch and S B Knoebel. Electrocardiographic findings in sertraline depression trials. *Drug Investigation*, 4(4):305–312, 1992.
- [279] P Danjou and D Hackett. Safety and tolerance profile of venlafaxine. *Int Clin Psychopharmacol*, 10 Suppl 2:15–20, 1995.
- [280] R Entsuaah, G V Upton, and R Rudolph. Efficacy of venlafaxine treatment in depressed patients with psychomotor retardation or agitation: a meta-analysis. *Hum Psychopharmacol*, 10:195–200, 1995.
- [281] A R Entsuaah, R L Rudolph, and R Chitra. Effectiveness of venlafaxine treatment in a broad spectrum of depressed patients: a meta-analysis. *Psychopharmacol Bull*, 31(4):759–66, 1995.
- [282] A R Entsuaah, H Huang, and M E Thase. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. *J Clin Psychiatry*, 62(11):869–877, 2001.
- [283] R Entsuaah and B Gao. Global benefit-risk evaluation of antidepressant action: comparison of pooled data for venlafaxine, SSRIs, and placebo. *CNS spectrums*, 7(12):882–888, 2002.
- [284] R D Gibbons, C H Brown, K Hur, J Davis, and J J Mann. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. *Arch Gen Psychiatry*, 69(6):580–7, 2012.
- [285] R Mallick, J Chen, A R Entsuaah, and A F Schatzberg. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: A comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. *J Clin Psychiatry*, 64(3):321–330, 2003.
- [286] J Mendlewicz. Pharmacologic profile and efficacy of venlafaxine. *Int Clin Psychopharmacol*, 10(suppl 2):5–13, 1995.
- [287] C B Nemeroff, R Entsuaah, I Benattia, M Demitrack, D M Sloan, and M E Thase. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. *Biol Psychiatry*, 63(4):424–434, 2008.
- [288] R L Rudolph, R Entsuaah, and R Chitra. A meta-analysis of the effects of venlafaxine on anxiety associated with depression. *J Clin Psychopharmacol*, 18(2):136–44, 1998.
- [289] C Shelton, R Entsuaah, S K Padmanabhan, and P E Vinall. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. *Int Clin Psychopharmacol*, 20(4):233–238, 2005.
- [290] P H Silverstone, R Entsuaah, and D Hackett. Two items on the Hamilton Depression rating scale are effective predictors of remission: comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxine. *Int Clin Psychopharmacol*, 17:273–280, 2002.
- [291] S M Stahl, R Entsuaah, and R L Rudolph. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. *Biol Psychiatry*, 52(12):1166–1174, 2002.
- [292] M E Thase, A R Entsuaah, and R L Rudolph. Remission rates during treatment with

-
- venlafaxine or selective serotonin reuptake inhibitors. *Br J Psychiatry*, 178(3):234–241, 2001.
- [293] M E Thase, R Entsuah, M Cantillon, and S G Kornstein. Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. *J Womens Health*, 14(7):609–16, 2005.
- [294] M H Trivedi, G J Wan, R Mallick, J Chen, R Casciano, E C Geissler, and J M Panish. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder. *J Clin Psychopharmacol*, 24(5):497–506, 2004.
- [295] A R Hariri, V S Mattay, A Tessitore, B S Kolachana, F Fera, D Goldman, M F Egan, and D R Weinberger. Serotonin transporter genetic variation and the response of the human amygdala. *Science*, 297(5580):400–403, 2002.
- [296] M R Munafò, S M Brown, and A R Hariri. Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis. *Biol Psychiatry*, 63(9):852–857, 2008.
- [297] S E Murphy, R Norbury, B R Godlewska, P J Cowen, Z M Mannie, C J Harmer, and M R Munafò. The effect of the serotonin transporter polymorphism (5-HTTLPR) on amygdala function: a meta-analysis. *Mol Psychiatry*, 18(4):512–20, 2013.
- [298] J A Bastiaansen, M N Servaas, J B C Marsman, J Ormel, I M Nolte, H Riese, and A Aleman. Filling the gap: relationship between the serotonin-transporter-linked polymorphic region and amygdala activation. *Psychol Sci*, 25(11):2058–2066, 2014.
- [299] R Bogdan, Luke W. Hyde, and A R Hariri. A neurogenetics approach to understanding individual differences in brain, behavior, and risk for psychopathology. *Mol Psychiatry*, 18(3):288–99, 2013.
- [300] I-U Park, M W Peacey, and M R Munafò. Modelling the effects of subjective and objective decision making in scientific peer review. *Nature*, 506(7486):93–6, 2014.
- [301] P F Sullivan, M C Neale, and K S Kendler. Genetic epidemiology of major depression: review and meta-analysis. *Am J Psychiatry*, 157:1552–1562, 2000.
- [302] C Hammen. Stress and depression. *Annual Review of Clinical Psychology*, 1:293–319, 2005.
- [303] A Caspi, A R Hariri, A Holmes, R Uher, and T E Moffitt. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. *Am J Psychiatry*, 167:509–527, 2010.
- [304] A Caspi, K Sugden, T E Moffitt, A Taylor, I W Craig, H L Harrington, J McClay, J Mill, J Martin, A W Braithwaite, and R Poulton. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. *Science*, 301(5631):386–9, 2003.
- [305] C F Sharpley, S K A Palanisamy, N S Glyde, P W Dillingham, and L L Agnew. An update on the interaction between the serotonin transporter promoter variant (5-HTTLPR), stress and depression, plus an exploration of non-confirming findings. *Behav Brain Res*, 273:89–105, 2014.
- [306] K Karg, M Burmeister, K Shedden, and S Sen. The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. *Arch Gen Psychiatry*, 68(5):444–54, 2011.
- [307] N Risch, R Herrell, T Lehner, KY Liang, L Eaves, J Hoh, A Griem, M Kovacs, J Ott, and K R Merikangas. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression. *JAMA*, 301(23):2462–2471, 2009.
- [308] Marcus R Munafò, Caroline Durrant, Glyn Lewis, and Jonathan Flint. Gene X environment interactions at the serotonin transporter locus. *Biol Psychiatry*, 65(3):211–9, feb 2009.
- [309] L E Duncan and M C Keller. A critical review of the first 10 years of candidate gene-by-environment interaction research in psychiatry. *Am J Psychiatry*, 168:1041–1049, 2011.
- [310] S Zammit, M J Owen, and G Lewis. Misconceptions about gene-environment interactions in psychiatry. *Evid Based Ment Health*, 13(3):65–68, 2010.
- [311] V E Heininga, A J Oldehinkel, R Veenstra, and E Nederhof. I just ran a thousand analyses: benefits of multiple testing in understanding equivocal evidence on gene-environment interactions. *PLOS ONE*, 10(5):e0125383, 2015.
- [312] P de Jonge, H J Conradi, B D Thombs, J G M Rosmalen, H Burger, and J Ormel. Prevention of false positive findings in observational studies: registration will not work but replication might. *Journal of Epidemiology and Community Health*, 65(2):95–96, 2011.

- [313] A-S Jannot, T Agoritsas, A Gayet-Ageron, and T V Perneger. Citation bias favoring statistically significant studies was present in medical research. *J Clin Epidemiol*, 66:296–301, 2013.
- [314] L L Kjaergard and C Gluud. Citation bias of hepato-biliary randomized clinical trials. *J Clin Epidemiol*, 55:407–410, 2002.
- [315] J A Bastiaansen, Y A de Vries, and M R Munafò. Citation distortions in the literature on the serotonin-transporter-linked polymorphic region and amygdala activation. *Biol Psychiatry*, 78(8):E35–36, 2015.
- [316] H A Whiteford, L Degenhardt, J Rehm, A J Baxter, A J Ferrari, H E Erskine, F J Charlson, R E Norman, A D Flaxman, N Johns, R Burstein, C J L Murray, and T Vos. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. *Lancet*, 382(9904):1575–1586, 2013.
- [317] J Martin, J Cleak, S A G Willis-Owen, Jonathan Flint, and S Shifman. Mapping regulatory variants for the serotonin transporter gene based on allelic expression imbalance. *Mol Psychiatry*, 12(5):421–422, 2007.
- [318] X Hu, G Oroszi, J Chun, T L Smith, D Goldman, and M A Schuckit. An expanded evaluation of the relationship of four alleles to the level of response to alcohol and the alcoholism risk. *Alcohol Clin Exp Res*, 29(1):8–16, 2005.
- [319] J R Wendland, B J Martin, M R Kruse, K-P Lesch, and D L Murphy. Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. *Mol Psychiatry*, 11(3):224–6, 2006.
- [320] F Song, S Parekh-Bhurke, L Hooper, Y K Loke, J J Ryder, A J Sutton, C B Hing, and I Harvey. Extent of publication bias in different categories of research cohorts: a meta-analysis of empirical studies. *BMC Med Res Methodol*, 9:79, 2009.
- [321] B A Nosek, J R Spies, and M Motyl. Scientific Utopia: II. Restructuring incentives and practices to promote truth over publishability. *Perspect Psychol Sci*, 7(6):615–631, 2012.
- [322] R C Culverhouse, L Bowes, N Breslau, J I Nurnberger, M Burmeister, D M Fergusson, M R Munafò, N L Saccone, and L J Bierut. Protocol for a collaborative meta-analysis of 5-HTTLPR, stress, and depression. *BMC Psychiatry*, 13:304, 2013.
- [323] S Every-Palmer and J Howick. How evidence-based medicine is failing due to biased trials and selective publication. *J Eval Clin Pract*, 20(6):908–914, 2014.
- [324] J Barth, T Munder, H Gerger, E Nüesch, S Trelle, H Znoj, P Jüni, and P Cuijpers. Comparative efficacy of seven psychotherapeutic interventions for patients with depression: a network meta-analysis. *PLOS Med*, 10(5):e1001454, 2013.
- [325] Michal Kicinski. How does under-reporting of negative and inconclusive results affect the false-positive rate in meta-analysis? A simulation study. *BMJ Open*, 4(8):e004831, 2014.
- [326] M W Otto and A A Nierenberg. Assay sensitivity, failed clinical trials, and the conduct of science. *Psychother Psychosom*, 71(5):241–3, 2002.
- [327] Y A de Vries, A M Roest, M Franzen, M R Munafò, and J A Bastiaansen. Citation bias and selective focus on positive findings in the literature on the serotonin transporter gene (5-HTTLPR), life stress and depression. *Psychol Med*, 46(14):2971 – 2979, 2016.
- [328] J Flint, P Cuijpers, J Horder, S L Koole, and M R Munafò. Is there an excess of significant findings in published studies of psychotherapy for depression? *Psychol Med*, 45(02):439–446, 2015.
- [329] D Rennie. Trial registration: a great idea switches from ignored to irresistible. *JAMA*, 292(11):1359–1362, 2004.
- [330] C D DeAngelis, J M Drazen, F A Frizelle, C Haug, J Hoey, R Horton, S Kotzin, C Laine, A Marusic, A J P M Overbeke, T V Schroeder, H C Sox, and M B Van Der Weyden. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. *JAMA*, 292(11):1363–1364, 2004.
- [331] H Knüppel, C Metz, J J Meerpohl, and D Strech. How psychiatry journals support the unbiased translation of clinical research. A cross-sectional study of editorial policies. *PLOS ONE*, 8(10):e75995, 2013.
- [332] S L Harriman and J Patel. When are clinical trials registered? An analysis of prospective versus retrospective registration. *Trials*, 17(1):187, 2016.
- [333] J S Ross, G K Mulvey, E M Hines, S E Nissen, and H M Krumholz. Trial publication after

-
- registration in ClinicalTrials.gov: A cross-sectional analysis. *PLOS Med*, 6(9):e1000144, 2009.
- [334] C W Jones, L G Keil, W C Holland, M C Caughey, and T F Platts-Mills. Comparison of registered and published outcomes in randomized controlled trials: a systematic review. *BMC Med*, 13(1):282, 2015.
- [335] Landelijke Stuurgroep Multidisciplinaire Richtlijnontwikkeling in de GGZ. Multidisciplinaire richtlijn: Addendum depressie bij jeugd. 2009.
- [336] National Institute for Health and Care Excellence. Depression in children and young people: Identification and management in primary, community and secondary care (2015 update). 2005.
- [337] Kinderformularium, <https://kinderformularium.nl>.
- [338] Kenniscentrum KJP, <http://www.kenniscentrum-kjp.nl>.
- [339] S E Hetrick, J E McKenzie, G R Cox, M B Simmons, and S N Merry. Newer generation antidepressants for depressive disorders in children and adolescents. *Cochrane Database Syst Rev*, (11):CD004851, 2012.
- [340] C J Whittington, T Kendall, P Fonagy, D Cottrell, A Cotgrove, and E Boddington. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. *Lancet*, 363(9418):1341–1345, 2004.
- [341] M Miller, S A Swanson, D Azrael, V Pate, and T Stürmer. Antidepressant dose, age, and the risk of deliberate self-harm. *JAMA Intern Med*, 174(6):899, 2014.
- [342] C Coupland, T Hill, R Morriss, A Arthur, M Moore, and J Hippisley-Cox. Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database. *BMJ*, 350:h517, 2015.
- [343] H-C Steinhausen. Recent international trends in psychotropic medication prescriptions for children and adolescents. *Eur Child Adolesc Psychiatry*, 24(6):635–640, 2015.
- [344] H-C Steinhausen and C Bisgaard. Nationwide time trends in dispensed prescriptions of psychotropic medication for children and adolescents in Denmark. *Acta Psychiatr Scand*, 129(3):221–31, 2014.
- [345] K R Merikangas, J-P He, J Rapoport, B Vitiello, and M Olfson. Medication use in US youth with mental disorders. *JAMA Pediatr*, 167(2):141–148, feb 2013.
- [346] L P M M Wijlaars, I Nazareth, and I Petersen. Trends in depression and antidepressant prescribing in children and adolescents: a cohort study in The Health Improvement Network (THIN). *PLOS ONE*, 7(3):e33181, 2012.
- [347] V Chirdkiatgumchai, H Xiao, B K Fredstrom, R E Adams, J N Epstein, S S Shah, W B Brinkman, R S Kahn, and T E Froehlich. National trends in psychotropic medication use in young children: 1994-2009. *Pediatrics*, 132(4):615–23, 2013.
- [348] J F Hernandez, A K Mantel-Teeuwisse, G J M W van Thiel, S V Belitser, Jan Warmerdam, V de Valk, J A M Raaijmakers, and T Pieters. A 10-year analysis of the effects of media coverage of regulatory warnings on antidepressant use in The Netherlands and UK. *PLOS ONE*, 7(9):e45515, 2012.
- [349] V Kovess, S Choppin, F Gao, M Pivette, M Husky, and E Leray. Psychotropic medication use in French children and adolescents. *J Child Adolesc Psychopharmacol*, 25(2):168–175, 2015.
- [350] F Hoffmann, G Glaeske, and C J Bachmann. Trends in antidepressant prescriptions for children and adolescents in Germany from 2005 to 2012. *Pharmacoepidemiol Drug Saf*, 23(12):1268–72, 2014.
- [351] G A Bushnell, T Stürmer, S A Swanson, A White, D Azrael, V Pate, and M Miller. Dosing of selective serotonin reuptake inhibitors among children and adults before and after the FDA black-box warning. *Psychiatr Serv*, 67(3):302–309, 2016.
- [352] Zorginstituut Nederland. GIP Databank, <https://www.gipdatabank.nl/>.
- [353] S T Visser, C C M Schuiling-Veninga, H J Bos, L T W de Jong-van den Berg, and M J Postma. The population-based prescription database IADB.nl: its development, usefulness in outcomes research and challenges. *Expert Rev Pharmacoecon Outcomes Res*, 13(3):285 – 292, 2013.
- [354] World Health Organization Collaborating Centre. *Introduction to drug utilization research*. 2003.
- [355] J R Strawn, J A Welge, A M Wehry, B Keeshin, and M A Rynn. Efficacy and tolerability

- of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis. *Depress Anxiety*, 32:149–157, 2015.
- [356] J C Ipser, D J Stein, S Hawkrigde, and L Hoppe. Pharmacotherapy for anxiety disorders in children and adolescents. *Cochrane Database Syst Rev*, (3):CD005170, 2009.
- [357] Food and Drug Administration. Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses, 2011.
- [358] S R Beach, W J Kostis, M Celano, J L Januzzi, J N Ruskin, P A Noseworthy, and J C Huffman. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. *J Clin Psychiatry*, 75(5):441–449, 2014.
- [359] X Meng, C D Arcy, and R Tempier. Long-term trend in pediatric antidepressant use, 1983 - 2007: a population-based study. *Can J Psychiatry*, 59(2):89–97, 2014.
- [360] A Pottegård, H Zoëga, J Hallas, and P Damkier. Use of SSRIs among Danish children: a nationwide study. *Eur Child Adolesc Psychiatry*, 23(12):1211–1218, 2014.
- [361] T A Sheldon, N Cullum, D Dawson, A Lankshear, K Lowson, I Watt, P West, D Wright, and J Wright. What’s the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients’ notes, and interviews. *BMJ*, 329(7473):999, 2004.
- [362] A Wazana. Physicians and the pharmaceutical industry: is a gift ever just a gift? *JAMA*, 283(3):373–380, 2000.
- [363] L J Cochrane, C A Olson, S Murray, M Dupuis, T Tooman, and S Hayes. Gaps between knowing and doing: understanding and assessing the barriers to optimal health care. *J Contin Educ Health Prof*, 27(2):94–102, 2007.
- [364] J M Grimshaw, M Eccles, and M A Tetrod. Implementing clinical guidelines: Current evidence and future implications. *J Contin Educ Health Prof*, 24:S31–S37, 2004.
- [365] R Grol and J Grimshaw. From best evidence to best practice: effective implementation of change in patients’ care. *Lancet*, 362(9391):1225–30, 2003.
- [366] S Michie and M Johnston. Changing clinical behaviour by making guidelines specific. *BMJ*, 328:343–345, 2004.
- [367] M L M Hermens, M Oud, H Sinnema, M H Nauta, Y Stikkelbroek, D van Duin, and M Wensing. The multidisciplinary depression guideline for children and adolescents: an implementation study. *Eur Child Adolesc Psychiatry*, 24(10):1207–1218, 2015.
- [368] J Grimshaw, M Eccles, R Thomas, G MacLennan, C Ramsay, C Fraser, and L Vale. Toward evidence-based quality improvement. *J Gen Intern Med*, 21(S2):S14–S20, 2006.
- [369] L Forsetlund, A Bjørndal, A Rashidian, G Jamtvedt, M A O’Brien, F M Wolf, D Davis, J Odgaard-Jensen, and A D Oxman. Continuing education meetings and workshops: effects on professional practice and health care outcomes. *Cochrane Database Syst Rev*, (2):CD003030, 2009.
- [370] A C Volkers, E R Heerdink, and L van Dijk. Antidepressant use and off-label prescribing in children and adolescents in Dutch general practice (2001-2005). *Pharmacoepidemiol Drug Saf*, 16:1054–1062, 2007.
- [371] L I Sinclair, D M Christmas, S D Hood, J P Potokar, A Robertson, A Isaac, S Srivastava, D J Nutt, and S J C Davies. Antidepressant-induced jitteriness/anxiety syndrome: Systematic review. *Br J Psychiatry*, 194(6):483–490, 2009.
- [372] GGZ Nederland. Sectorrapport GGZ 2012. Technical report, 2014.
- [373] S E Bruce, K A Yonkers, M W Otto, J L Eisen, R B Weisberg, M Pagano, M T Shea, and M B Keller. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. *Am J Psychiatry*, 162:1179–1187, 2005.
- [374] R A Hansen, B N Gaynes, G Gartlehner, C G Moore, R Tiwari, and K N Lohr. Efficacy and tolerability of second-generation antidepressants in social anxiety disorder. *Int Clin Psychopharmacol*, 23(3):170–9, 2008.
- [375] C Barbui, A Cipriani, V Patel, J L Ayuso-Mateos, and M van Ommeren. Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis. *Br J Psychiatry*, 198(1):11–6, 2011.
- [376] A Khan, A Bhat, J Faucett, R L Kolts, and W A Brown. Antidepressant-placebo differences in 16 clinical trials over 10 years at a single site: role of baseline severity. *Psychopharmacology*, 214(4):961–5, 2011.

-
- [377] D J Stein, M B Stein, and C D Pitts. Predictors of response to pharmacotherapy in social anxiety disorder: An analysis of 3 placebo-controlled paroxetine trials. *J Clin Psychiatry*, 63(2):152–155, 2002.
- [378] S A Montgomery. Implications of the severity of social phobia. *J Affect Disord*, 50(suppl 1):S17–22, 1998.
- [379] M H Pollack, P Meoni, M W Otto, and D Hackett. Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short-and long-term studies. *J Clin Psychopharmacol*, 23(3):250–259, 2003.
- [380] S B Morris and R P DeShon. Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs. *Psychol Methods*, 7(1):105–125, 2002.
- [381] M Adli, C Baethge, A Heinz, N Langlitz, and M Bauer. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. *Eur Arch Psychiatry Clin Neurosci*, 255(6):387–400, 2005.
- [382] J P A Ioannidis and T A Trikalinos. An exploratory test for an excess of significant findings. *Clin Trials*, 4(3):245–53, 2007.
- [383] M Hoskins, J Pearce, A Bethell, L Dankova, C Barbui, W A Tol, M van Ommeren, J de Jong, S Seedat, H Chen, and J I Bisson. Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. *Br J Psychiatry*, 206(2):93–100, 2015.
- [384] C Allgulander, A A Dahl, C Austin, P L P Morris, J A Sogaard, R Fayyad, S P Kutcher, and C M Clary. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. *Am J Psychiatry*, 161(9):1642–1649, 2004.
- [385] D S Baldwin, A K T Huusom, and E Maehlum. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. *Br J Psychiatry*, 189(10):264–272, 2006.
- [386] B Bandelow, G Chouinard, J Bobes, A Ahokas, I Eggens, S Liu, and H Eriksson. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. *Int J Neuropsychopharmacol*, 13(3):305–320, 2010.
- [387] O Brawman-Mintzer, R G Knapp, M Rynn, R E Carter, and K Rickels. Sertraline treatment for generalized anxiety disorder: A randomized, double-blind, placebo-controlled study. *J Clin Psychiatry*, 67(6):874–881, 2006.
- [388] D Hackett, V Haudiquet, and E Salinas. A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder. *Eur Psychiatry*, 18(4):182–187, 2003.
- [389] S Kasper, B Herman, G Nivoli, M Van Ameringen, A Petralia, F S Mandel, F Baldinetti, and B Bandelow. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. *Int Clin Psychopharmacol*, 24(2):87–96, 2009.
- [390] C Merideth, A J Cutler, F She, and H Eriksson. Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder. *Int Clin Psychopharmacol*, 27(1):40–54, 2012.
- [391] H Nicolini, D Bakish, H Duenas, M Spann, J Erickson, C Hallberg, S Ball, D Sagman, and J M Russell. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. *Psychol Med*, 39(2):267–276, 2009.
- [392] I Nimatoudis, N P Zissis, J Kogeorgos, S Theodoropoulou, A Vidalis, and G Kaprinis. Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study. *Int Clin Psychopharmacol*, 19(6):331–336, 2004.
- [393] C Allgulander. Paroxetine in social anxiety disorder: a randomized placebo-controlled study. *Acta Psychiatr Scand*, 100(3):193–198, 1999.
- [394] C Allgulander, R Mangano, J Zhang, A A Dahl, U Lepola, I Sjödin, G Emilien, H J Nyrerod, P Ostergaard, J Peltz, H Philippi, F X Poudat, S Rasmussen, G Schumann, E Tjora, and N Vaillant-Pelle. Efficacy of venlafaxine ER in patients with social anxiety disorder: A double-blind, placebo-controlled, parallel-group comparison with paroxetine. *Hum Psychopharmacol*, 19(6):387–396, 2004.
- [395] S Asakura, O Tajima, and T Koyama. Fluvoxamine treatment of generalized social anxiety

- disorder in Japan: a randomized double-blind, placebo-controlled study. *Int J Neuropsychopharmacol*, 10(2):263–274, 2007.
- [396] D M Clark, A Ehlers, F McManus, A Hackmann, M Fennell, H Campbell, T Flower, C Davenport, and B Louis. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. *J Consult Clin Psychol*, 71(6):1058–1067, 2003.
- [397] S Kasper, D J Stein, H Loft, and R Nil. Escitalopram in the treatment of social anxiety disorder. *Br J Psychiatry*, 186(3):222–226, 2005.
- [398] K A Kobak, J H Greist, J W Jefferson, and D J Katzelnick. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. *J Clin Psychopharmacol*, 22(3):257–262, 2002.
- [399] M Lader, K Stender, V Bürger, and R Nil. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. *Depress Anxiety*, 19(4):241–8, 2004.
- [400] M R Liebowitz, A J Gelenberg, and D Munjack. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. *Arch Gen Psychiatry*, 62(2):190–198, 2005.
- [401] M B Stein, A J Fyer, J R Davidson, M H Pollack, and B Wiita. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. *Am J Psychiatry*, 156(5):756–760, 1999.
- [402] I M van Vliet, J A den Boer, and H G Westenberg. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. *Psychopharmacology*, 115(1-2):128–134, 1994.
- [403] M A Jenike, S Hyman, L Baer, A Holland, W E Minichiello, L Buttolph, P Summergrad, R Seymour, and J N Ricciardi. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. *Am J Psychiatry*, 147(9):1209–1215, 1990.
- [404] M A Jenike, L Baer, P Summergrad, W E Minichiello, A Holland, and R Seymour. Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo. *Am J Psychiatry*, 147:923–928, 1990.
- [405] M A Jenike, L Baer, W E Minichiello, S L Rauch, and M L Buttolph. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. *Am J Psychiatry*, 154(9):1261–1264, 1997.
- [406] K Kamijima, M Murasaki, M Asai, T Higuchi, T Nakajima, C Taga, and H Matsunaga. Paroxetine in the treatment of obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study in Japanese patients. *Psychiatry Clin Neurosci*, 58:427–433, 2004.
- [407] S A Montgomery, S Kasper, D J Stein, K Bang Hedegaard, and O M Lemming. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. *Int Clin Psychopharmacol*, 16(2):75–86, 2001.
- [408] E Nakatani, A Nakagawa, T Nakao, C Yoshizato, M Nabeyama, A Kudo, K Isomura, N Kato, K Yoshioka, and M Kawamoto. A randomized controlled trial of Japanese patients with obsessive-compulsive disorder—effectiveness of behavior therapy and fluvoxamine. *Psychother Psychosom*, 74(5):269–276, 2005.
- [409] J Davidson, D Baldwin, D J Stein, E Kuper, I Benattia, S Ahmed, R Pedersen, and J Musngung. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. *Arch Gen Psychiatry*, 63(10):1158–1165, 2006.
- [410] R D Marshall, R Lewis-Fernandez, C Blanco, H B Simpson, S-H Lin, D Vermes, W Garcia, F Schneier, Y Neria, A Sanchez-Lacay, and M R Liebowitz. A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. *Depress Anxiety*, 24(2):77–84, 2007.
- [411] F Martenyi, E B Brown, H Zhang, A Prakash, and S C Koke. Fluoxetine versus placebo in posttraumatic stress disorder. *J Clin Psychiatry*, 63:199–206, 2002.
- [412] F Martenyi, E B Brown, and C D Caldwell. Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study. *J Clin Psychopharmacol*, 27(2):166–170, 2007.
- [413] P Tucker, R Potter-Kimball, D B Wyatt, D E Parker, C Burgin, D E Jones, and B K Masters. Can physiologic assessment and side effects tease out differences in PTSD trials?

-
- A double-blind comparison of citalopram, sertraline, and placebo. *Psychopharmacol Bull*, 37(3):135–149, 2003.
- [414] B A Van Der Kolk, J Spinazzola, M E Blaustein, J W Hopper, E K Hopper, D L Korn, and W B Simpson. A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. *J Clin Psychiatry*, 68(1):37–46, 2007.
- [415] G M Asnis, F A Hameedi, A W Goddard, S G Potkin, D Black, M Jameel, K Desagani, and S W Woods. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. *Psychiatry Res*, 103(1):1–14, 2001.
- [416] E de Beurs, A J L M van Balkom, A Lange, P Koele, and R van Dyck. Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. *Am J Psychiatry*, 152(5):683–691, 1995.
- [417] N P Nair, D Bakish, B Saxena, M Amin, G Schwartz, and T E West. Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. *Anxiety*, 2(4):192–198, 1996.
- [418] M H Pollack, J J Worthington III, M W Otto, K M Maki, J W Smoller, G G Manfro, R Rudolph, and J F Rosenbaum. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. *Psychopharmacol Bull*, 32(4):667–670, 1996.
- [419] S M Stahl, I Gergel, and D Li. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry*, 64:1322–1327, 2003.
- [420] M B Stein, G Ron Norton, J R Walker, M J Chartier, and R Graham. Do selective serotonin re-uptake inhibitors enhance the efficacy of very brief cognitive behavioral therapy for panic disorder? A pilot study. *Psychiatry Res*, 94(3):191–200, 2000.
- [421] S Leucht, S Hierl, W Kissling, M Dold, and J M Davis. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. *Br J Psychiatry*, 200(2):97–106, 2012.
- [422] H C Kraemer and D J Kupfer. Size of treatment effects and their importance to clinical research and practice. *Biol Psychiatry*, 59(11):990–6, 2006.
- [423] P Cuijpers, E H Turner, S L Koole, A van Dijke, and F Smit. What is the threshold for a clinically relevant effect? The case of major depressive disorders. *Depress Anxiety*, 31(5):374–378, 2014.
- [424] National Institute of Clinical Excellence. Common mental health disorders: Identification and pathways to care (clinical guideline 123). Technical report, 2011.
- [425] H Baumeister. Inappropriate prescriptions of antidepressant drugs in patients with sub-threshold to mild depression: time for the evidence to become practice. *J Affect Disord*, 139(3):240–3, 2012.
- [426] J Spijker, R de Graaf, R V Bijl, A T F Beekman, J Ormel, and W A Nolen. Duration of major depressive episodes in the general population: results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). *Br J Psychiatry*, 181(3):208–213, 2002.
- [427] S M Hendriks, J Spijker, C M M Licht, A T F Beekman, and B W J H Penninx. Two-year course of anxiety disorders: different across disorders or dimensions? *Acta Psychiatr Scand*, 128(3):212–21, 2013.
- [428] National Institute of Clinical Excellence. Depression in adults: the treatment and management of depression in adults. NICE clinical guideline 90. Technical report, 2009.
- [429] D Michelson, C Allgulander, K Dantendorfer, A Knezevic, D Maierhofer, V Micev, V R Paunovic, I Timotijevic, N Sarkar, L Skoglund, and S C Pemberton. Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial. *Br J Psychiatry*, 179:514–518, 2001.
- [430] T A Furukawa, S Z Levine, S Tanaka, Y Goldberg, M Samara, J M Davis, A Cipriani, and S Leucht. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. *JAMA Psychiatry*, 72(1):14, 2015.
- [431] M L Davis, J A Smits, and S G Hofmann. Update on the efficacy of pharmacotherapy for social anxiety disorder: a meta-analysis. *Expert opinion on pharmacotherapy*, 15(16):2281–2291, nov 2014.
- [432] J Curtiss, L Andrews, M Davis, J Smits, and S G Hofmann. A meta-analysis of phar-

- macotherapy for social anxiety disorder: an examination of efficacy, moderators, and mediators. *Expert opinion on pharmacotherapy*, 18(3):243–251, feb 2017.
- [433] Y A de Vries, P de Jonge, E van den Heuvel, E H Turner, and A M Roest. Influence of baseline severity on antidepressant efficacy for anxiety disorders: Meta-analysis and meta-regression. *Br J Psychiatry*, 208(6):515–521, 2016.
- [434] S G Thompson and J P T Higgins. How should meta-regression analyses be undertaken and interpreted? *Statistics in Medicine*, 21(11):1559–73, 2002.
- [435] Dan J Stein, Siegfried Kasper, Elisabeth Wreford Andersen, Rico Nil, and Malcolm Lader. Escitalopram in the treatment of social anxiety disorder: Analysis of efficacy for different clinical subgroups and symptom dimensions. *Depression and Anxiety*, 20(4):175–181, 2004.
- [436] Chi-Un Pae, Sheng-Min Wang, Changsu Han, Soo-Jung Lee, Ashwin A Patkar, Praksh S Masand, and Alessandro Serretti. Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis. *J Psychiatr Res*, 64:88–98, may 2015.
- [437] S A Montgomery, D V Sheehan, P Meoni, V Haudiquet, and D Hackett. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. *Journal of psychiatric research*, 36(4):209–217, 2002.
- [438] D J Stein, M B Stein, W Goodwin, R Kumar, and B Hunter. The selective serotonin reuptake inhibitor paroxetine is effective in more generalized and in less generalized social anxiety disorder. *Psychopharmacology*, 158(3):267–272, nov 2001.
- [439] M J Friedman, C R Marmar, D G Baker, C R Sikes, and G M Farfel. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. *The Journal of clinical psychiatry*, 68(5):711–720, may 2007.
- [440] Douglas G Altman and Patrick Royston. The cost of dichotomising continuous variables. *BMJ*, 332(7549):1080–1080, 2006.
- [441] Clinical Study Data Request, <https://clinicalstudydatarequest.com>.
- [442] GlaxoSmithKline. GSK Clinical Study Register, <http://www.gsk-clinicalstudyregister.com>.
- [443] Lilly. Lilly Clinical Trial Registry, <https://www.lilly.com/clinical-study-registration-and-results>.
- [444] GlaxoSmithKline. BRL29060A/661. Clinical evaluation of BRL29060A (paroxetine hydrochloride hydrate) in social phobia/social anxiety disorder (SAD) - a double-blind, placebo-controlled study.
- [445] GlaxoSmithKline. PIR104776. Clinical evaluation of BRL29060A (paroxetine hydrochloride hydrate) in social phobia/social anxiety disorder (SAD) - a double-blind, placebo-controlled study.
- [446] GlaxoSmithKline. BRL29060A/856. Clinical evaluation of BRL29060A (paroxetine hydrochloride hydrate) in generalized anxiety disorder (GAD) - a double-blind, placebo-controlled, comparative study.
- [447] K T Forbush and D Watson. The structure of common and uncommon mental disorders. *Psychol Med*, 43(1):97–108, 2013.
- [448] K M Keyes, N R Eaton, R F Krueger, A E Skodol, M M Wall, B Grant, L J Siever, and D S Hasin. Thought disorder in the meta-structure of psychopathology. *Psychol Med*, 43(8):1673–83, 2013.
- [449] B L Rollman, B H Belnap, S Mazumdar, F Zhu, K Kroenke, H C Schulberg, and K M Shear. Symptomatic severity of PRIME-MD diagnosed episodes of panic and generalized anxiety disorder in primary care. *Journal of General Internal Medicine*, 20(7):623–8, 2005.
- [450] M Katherine Shear, Timothy A Brown, David H Barlow, Roy Money, Diane E Sholomskas, Scott W Woods, Jack M Gorman, and Laszlo A Papp. Multicenter collaborative panic disorder severity scale. *Am J Psychiatry*, 154:1571–1575, 1997.
- [451] H Kraemer, G A Morgan, N Leech, J A Gliner, J J Vaske, and R J Harmon. Measures of clinical significance. *The American Academy of Child and Adolescent Psychiatry*, 42(12):1524–1529, 2003.
- [452] Lilly. A comparison of duloxetine hydrochloride, venlafaxine- extended release , and placebo in the treatment of generalized anxiety disorder (study HMDW).

-
- [453] GlaxoSmithKline Clinical Study Register. A randomized, double-blind, placebo-controlled, flexible dosage trial to evaluate the efficacy and tolerability of paroxetine CR in patients with generalized anxiety disorder (GAD) (study 29060/791).
- [454] GlaxoSmithKline Clinical Study Register. Paroxetine versus clomipramine and placebo in the treatment of obsessive-compulsive disorder (study 118).
- [455] GlaxoSmithKline Clinical Study Register. A double-blind, multicentered, flexible-dose study of paroxetine, alprazolam and placebo in the treatment of panic disorder (study 223).
- [456] M J Taylor, N Freemantle, J R Geddes, and Z Bhagwagar. Early onset of selective serotonin reuptake inhibitor antidepressant action: a systematic review and meta-analysis. *Arch Gen Psychiatry*, 63:1217 – 1223, 2006.
- [457] H H Stassen, J Angst, D Hell, C Scharfetter, and A Szegedi. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. *J Clin Psychiatry*, 68(8):1195–1205, 2007.
- [458] V Henkel, F Seemüller, M Obermeier, M Adli, M Bauer, K Kronmüller, F Holsboer, P Brieger, G Laux, W Bender, I Heuser, J Zeiler, W Gaebel, A Mayr, M Riedel, and H-J Möller. Relationship between baseline severity of depression and antidepressant treatment outcome. *Pharmacopsychiatry*, 44:27–32, 2011.
- [459] J M Kim, S Y Kim, R Stewart, J A Yoo, K Y Bae, S W Jung, M S Lee, H W Yim, and T Y Jun. Improvement within 2 weeks and later treatment outcomes in patients with depressive disorders: The CRESCEND study. *J Affect Disord*, 129(1-3):183–190, 2011.
- [460] H A Sackeim, S P Roose, and P W Lavori. Determining the duration of antidepressant treatment: Application of signal detection methodology and the need for duration adaptive designs (DAD). *Biol Psychiatry*, 59(6):483–492, 2006.
- [461] P Gorwood, F Bayle, G Vaiva, P Courtet, E Corruble, and P-M Llorca. Is it worth assessing progress as early as week 2 to adapt antidepressive treatment strategy? Results from a study on agomelatine and a global meta-analysis. *Eur Psychiatry*, 28(6):362–371, 2013.
- [462] R Uher, R H Perlis, N Henigsberg, A Zobel, M Rietschel, O Mors, J Hauser, M Z Dernovsek, D Souery, M Bajs, W Maier, K J Aitchison, A Farmer, and P McGuffin. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. *Psychol Med*, 42(05):967–980, 2012.
- [463] J Mizushima, H Uchida, M Tada, T Suzuki, M Mimura, and S Nio. Early improvement of specific symptoms predicts subsequent recovery in bipolar depression. *J Clin Psychiatry*, 78(02):e146–e151, 2017.
- [464] I Berlin and F Lavergne. Early predictors of two month response with mianserin and selective serotonin reuptake inhibitors and influence of definition of outcome on prediction. *Eur Psychiatry*, 13(3):138–142, 1998.
- [465] A H Farabaugh, S Bitran, J Witte, J Alpert, S Chuzi, A J Clain, L Baer, M Fava, P J McGrath, C Dording, D Mischoulon, and G I Papakostas. Anxious depression and early changes in the HAM-D-17 anxiety-somatization factor items and antidepressant treatment outcome. *Int Clin Psychopharmacol*, 25(4):214–217, 2010.
- [466] S Leucht, H Fennema, R Engel, M Kaspers-Janssen, P Lepping, and A Szegedi. What does the HAM-D mean? *J Affect Disord*, 148(2-3):243–248, 2013.
- [467] R Tibshirani. Regression selection and shrinkage via the lasso. *J R Stat Soc Series B Stat Methodol*, 58(1):267–288, 1996.
- [468] J Friedman, T Hastie, and R Tibshirani. Regularization paths for generalized linear models via coordinate descent. *J Stat Softw*, 33(1):1–22, 2010.
- [469] M A Posternak, L Baer, A A Nierenberg, and M Fava. Response rates to fluoxetine in subjects who initially show no improvement. *J Clin Psychiatry*, 72(7):949–954, 2011.
- [470] T Bschor, H Kern, J Henssler, and C Baethge. Switching the antidepressant after nonresponse in adults with major depression: a systematic literature search and meta-analysis. *J Clin Psychiatry*, 77, 2016.
- [471] H G Ruhé, J Huyser, J A Swinkels, and A H Schene. Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder - systematic review. *Br J Psychiatry*, 189:309–316, 2006.
- [472] X Zhou, A V Ravindran, B Qin, C Del Giovane, Q Li, M Bauer, Y Liu, Y Fang, T da Silva,

- Y Zhang, L Fang, X Wang, and P Xie. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression. *J Clin Psychiatry*, 76(4):e487–e498, 2015.
- [473] F Hieronymus, S Nilsson, and E Eriksson. A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors. *Translational Psychiatry*, 6(6):e834, 2016.
- [474] E Jakubovski, A L Varigonda, N Freemantle, M J Taylor, and M H Bloch. Systematic review and meta-analysis: dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder. *Am J Psychiatry*, 54(7):557 – 564, 2015.
- [475] S R Wisniewski, A J Rush, A A Nierenberg, B N Gaynes, D Warden, J F Luther, P J McGrath, P W Lavori, M E Thase, M Fava, and M H Trivedi. Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. *Am J Psychiatry*, 166(5):599–607, 2009.
- [476] GSK Clinical Trial Registry. A phase II, placebo-controlled, double-blind study of paroxetine in depressed outpatients (29060/01/001).
- [477] G C Dunbar, J L Claghorn, Ari Kiev, Karl Rickels, and W T Smith. A comparison of paroxetine and placebo in depressed outpatients. *Acta Psychiatr Scand*, 87(5):302–305, 1993.
- [478] GSK Clinical Trial Registry. A double-blind comparison of paroxetine, amitriptyline, and placebo in inpatients with major depressive disorder with melancholia (29060/07/001).
- [479] GSK Clinical Trial Registry. A multicenter, double-blind, placebo-controlled fixed-dose evaluation of four doses of paroxetine (29060/009).
- [480] GSK Clinical Trial Registry. A multicenter, randomized, double-blind, placebo-controlled comparison of paroxetine and fluoxetine in the treatment of major depressive disorder (29060/115).
- [481] GSK Clinical Trial Registry. A multicenter, randomized, double-blind, placebo-controlled comparison of paroxetine and fluoxetine in the treatment of major depressive disorder (29060/128).
- [482] J G Edwards and A Goldie. Placebo-controlled trial of paroxetine in depressive illness. *Hum Psychopharmacol*, 8(3):203–209, 1993.
- [483] GSK Clinical Trial Registry. A study to assess the effectiveness and tolerance of paroxetine by double-blind comparison with placebo and mianserin (29060/012-3).
- [484] M H Rapaport, L S Schneider, D L Dunner, J T Davies, and C D Pitts. Efficacy of controlled-release paroxetine in the treatment of late-life depression. *J Clin Psychiatry*, 64(9):1065–1074, 2003.
- [485] M H Trivedi, T A Pigotti, P Perera, K E Dillingham, M L Carfagno, and C D Pitts. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. *J Clin Psychiatry*, 65(10):1356–64, 2004.
- [486] D J Goldstein, C Mallinckrodt, Y Lu, and M A Demitrack. Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial. *J Clin Psychiatry*, 63(3):225–231, 2002.
- [487] Lilly clinical trial registry. Duloxetine versus placebo in the treatment of major depression (HMAQ-B).
- [488] Lilly clinical trial registry. Duloxetine versus placebo and paroxetine in the acute treatment of major depression (HMAT-A), 2004.
- [489] D J Goldstein, Y Lu, M J Detke, C Wiltse, C Mallinckrodt, and M A Demitrack. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. *J Clin Psychopharmacol*, 24(4):389–399, 2004.
- [490] M J Detke, C G Wiltse, C H Mallinckrodt, R K McNamara, M A Demitrack, and I Bitter. Duloxetine in the acute and long-term treatment of major depressive disorder: A placebo- and paroxetine-controlled trial. *Eur Neuropsychopharmacol*, 14(6):457–470, 2004.
- [491] D G S Perahia, F Wang, C H Mallinckrodt, D J Walker, and M J Detke. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. *Eur Psychiatry*, 21(6):367–378, sep 2006.
- [492] M J Detke, Y Lu, D J Goldstein, J R Hayes, and M A Demitrack. Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial. *J Clin Psychiatry*, 63(4):308–315, 2002.

-
- [493] M J Detke, Y Lu, D J Goldstein, R K McNamara, and M A Demitrack. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. *J Psychiatr Res*, 36(6):383–390, 2002.
- [494] D G S Perahia, Y L Pritchett, D K Kajdasz, M Bauer, R Jain, J M Russell, D J Walker, K A Spencer, D M Froud, J Raskin, and M E Thase. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. *J Psychiatr Res*, 42(1):22–34, 2008.
- [495] A A Nierenberg, J H Greist, C H Mallinckrodt, A Prakash, A Sambunaris, G D Tollefson, and M M Wohlreich. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. *Curr Med Res Opin*, 23(2):401–416, 2007.
- [496] P Lee, L Shu, X Xu, C Y Wang, M S Lee, C Y Liu, J P Hong, S Ruschel, J Raskin, S A Colman, and G A Harrison. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: Multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil. *Psychiatry Clin Neurosci*, 61(3):295–307, 2007.
- [497] T M Oakes, C Katona, P Liu, M Robinson, J Raskin, and J H Greist. Safety and tolerability of duloxetine in elderly patients with major depressive disorder: a pooled analysis of two placebo-controlled studies. *Int Clin Psychopharmacol*, 28(1):1–11, 2013.
- [498] T M M Oakes, A L Myers, L B Marangell, J Ahl, A Prakash, M E Thase, and S G Kornstein. Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: Primary outcomes from two trials conducted under the same protocol. *Hum Psychopharmacol*, 27(1):47–56, 2012.
- [499] GSK Clinical Trial Registry. An 8-week, randomized, double-blind, placebo-controlled, multicenter, fixed-dose study comparing the efficacy and safety of a new chemical entity (NCE) or paroxetine to placebo in moderately to severely depressed patients with major depressive disorder (NKD200006).
- [500] GSK Clinical Trial Registry. A randomised, double-blind, double-dummy, parallel-group, placebo-controlled, forced dose titration study evaluating the efficacy and safety of a new chemical entity (NCE) and paroxetine in subjects with major depressive disorder (NKF100096).
- [501] O A Panagiotou and J P A Ioannidis. Primary study authors of significant studies are more likely to believe that a strong association exists in a heterogeneous meta-analysis compared with methodologists. *J Clin Epidemiol*, 65(7):740–747, 2012.
- [502] I Shrier, J-F Boivin, R W Platt, R J Steele, J M Brophy, F Carnevale, M J Eisenberg, A Furlan, R Kakuma, M E Macdonald, L Pilote, and M Rossignol. The interpretation of systematic reviews with meta-analyses: an objective or subjective process? *BMC Med Inform Decis Mak*, 8:19, 2008.
- [503] R Dal-Ré, J S Ross, and A Marušić. Compliance with prospective trial registration guidance remained low in high-impact journals and has implications for primary end point reporting. *J Clin Epidemiol*, 75:100–107, 2016.
- [504] ClinicalTrials.gov. FDAAA 801 Requirements, <https://clinicaltrials.gov/ct2/manage-recs/fdaaa>.
- [505] M L Anderson, K Chiswell, E D Peterson, A Tasneem, J Topping, and R M Califf. Compliance with results reporting at ClinicalTrials.gov. *N Engl J Med*, 372(11):1031–9, 2015.
- [506] L Hirsch. Trial registration and results disclosure: impact of US legislation on sponsors, investigators, and medical journal editors. *Curr Med Res Opin*, 24(6):1683–1689, 2008.
- [507] Open Science Framework, <https://osf.io/8mpji/wiki/home>. Registered reports.
- [508] R A Fisher. Presidential Address. *Sankhya*, 4(1):14–17, 1938.
- [509] D H Marin dos Santos and A N Atallah. FDAAA legislation is working, but methodological flaws undermine the reliability of clinical trials: a cross-sectional study. *PeerJ*, 3:e1015, 2015.
- [510] B Rawal and B R Deane. Clinical trial transparency: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved recently in Europe. *Curr Med Res Opin*, 30(3):395–405, 2014.

- [511] Y A de Vries, E H Turner, and A M Roest. Retraction of biased journal articles. *BMJ*, 351:h5497, 2015.
- [512] Restoring Study 329, <https://study329.org>.
- [513] G M Asnis and M A Henderson. Levomilnacipran for the treatment of major depressive disorder: A review. *Neuropsychiatr Dis Treat*, 11:125–135, 2015.
- [514] A Matheson. The disposable author: how pharmaceutical marketing is embraced within medicine’s scholarly literature. *Hastings Cent Rep*, 46(4):31–37, 2016.
- [515] J E Miller. From bad pharma to good pharma: Aligning market forces with good and trustworthy practices through accreditation, certification, and rating. *J Law Med Ethics*, 41(3):601–610, 2013.
- [516] Access to Medicine Index, <http://accesstomedicineindex.org>.
- [517] A Schafer. Biomedical conflicts of interest: a defence of the sequestration thesis-learning from the cases of Nancy Olivieri and David Healy. *J Med Ethics*, 30:8–24, 2004.
- [518] F Leichsenring, A Abbass, M J Hilsenroth, F Leweke, P Luyten, J R Keefe, N Midgley, S Rabung, S Salzer, and C Steinert. Biases in research: risk factors for non-replicability in psychotherapy and pharmacotherapy research. *Psychol Med*, 47(6):1000–1011, 2016.
- [519] D Van Dijk, O Manor, and L B Carey. Publication metrics and success on the academic job market. *Curr Biol*, 24(11):R516–R517, 2014.
- [520] F C Fang and A Casadevall. Retracted science and the retraction index. *Infect Immun*, 79(10):3855–3859, 2011.
- [521] P E Smaldino and R McElreath. The natural selection of bad science. *Royal Soc Open Sci*, 3:160384, 2016.
- [522] A D Higginson and M R Munafò. Current incentives for scientists lead to underpowered studies with erroneous conclusions. *PLOS Biology*, 14(11):e2000995, 2016.
- [523] S Moore, C Neylon, M P Eve, D P O’Donnell, and D Pattinson. “Excellence R Us”: university research and the fetishisation of excellence. *Palgrave Communications*, 3:16105, 2017.
- [524] D J Benos, E Bashari, J M Chaves, A Gaggar, N Kapoor, M LaFrance, R Mans, D Mayhew, S McGowan, A Polter, Y Qadri, S Sarfare, K Schultz, R Splittgerber, J Stephenson, Cr Tower, R G Walton, and A Zotov. The ups and downs of peer review. *Adv Physiol Educ*, 31(2):145–152, 2007.
- [525] R C Culverhouse, N L Saccone, A C Horton, Y Ma, K J Anstey, and T Banaschewski et al. Collaborative meta-analysis finds no evidence of a strong interaction between stress and 5-HTTLPR genotype contributing to the development of depression. *Mol Psychiatry*, (online-first):1–10, 2017.
- [526] M S Bauer. A review of quantitative studies of adherence to mental health clinical practice guidelines. *Harv Rev Psychiatry*, 10(3):138–153, 2002.
- [527] R Grol, J Dalhuijsen, S Thomas, C Veld, G Rutten, and H Mokkink. Attributes of clinical guidelines that influence use of guidelines in general practice: observational study. *BMJ*, 317(7162):858–861, 1998.
- [528] D Herzberg. *Happy pills in America: from Miltown to Prozac*. 2010.
- [529] P D Kramer. *Listening to Prozac*. 1993.
- [530] Laura A Pratt, Debra J Brody, and Q Gu. Antidepressant use in persons aged 12 and over: United States, 2005–2008. *NCHS Data Brief*, 76, 2011.
- [531] P C Gotzsche. *Deadly psychiatry and organised denial*. 2015.
- [532] I Kirsch. *The emperor’s new drugs: exploding the antidepressant myth*. Hachette Book Group, 2010.
- [533] R Whitaker. *Anatomy of an epidemic: magic bullets, psychiatric drugs, and the astonishing rise of mental illness in America*. Broadway Books, 2010.
- [534] W Rief, Y Nestoriuc, A Von Lilienfeld-Toal, I Dogan, Fra Schreiber, S G Hofmann, A J Barsky, and J Avorn. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: A systematic review and meta-analysis. *Drug Saf*, 32(11):1041–1056, 2009.
- [535] I Kirsch. The emperor’s new drugs: medication and placebo in the treatment of depression. In F Benedetti, P Enck, E Frisaldi, and M Schedlowski, editors, *Placebo*, pages 291 – 303. Springer, 2014.

-
- [536] N C Savill, J K Buitelaar, E Anand, K A Day, T Treuer, H P Upadhyaya, and D Coghill. The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A comprehensive review of over a decade of clinical research. *CNS Drugs*, 29(2):131–151, 2015.
- [537] A Aftab, C Chen, and J McBride. Flibanserin and its discontents. *Arch Womens Ment Health*, 20(2):243–247, 2017.
- [538] W F Gellad, K E Flynn, and G C Alexander. Evaluation of flibanserin: science and advocacy at the FDA. *JAMA*, 314(9):869–870, 2015.
- [539] R P Greenberg, R F Bornstein, M J Zborowski, S Fisher, and M D Greenberg. A meta-analysis of fluoxetine outcome in the treatment of depression. *J Nerv Ment Dis*, 182(10):547–551, 1994.
- [540] M Barth, L Kriston, S Klostermann, Corrado Barbui, Andrea Cipriani, and K Linde. Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials. *Br J Psychiatry*, 208(2):114–119, 2016.
- [541] I Bighelli, A Borghesani, and C Barbui. Is the efficacy of antidepressants in panic disorder mediated by adverse events? A mediational analysis. *PLOS ONE*, 12(6):e0178617, 2017.
- [542] F Hieronymus, A Lisinski, S Nilsson, and E Eriksson. Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression. *Mol Psychiatry*, (online-first):1–6, 2017.
- [543] P Cuijpers, A van Straten, E Bohlmeijer, S D Hollon, and G Andersson. The effects of psychotherapy for adult depression are overestimated: a meta-analysis of study quality and effect size. *Psychol Med*, 40(2):211–23, 2010.
- [544] P Cuijpers, M Sijbrandij, S L Koole, G Andersson, A T F Beekman, and C F Reynolds. The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons. *World Psychiatry*, 12(2):137–48, 2013.
- [545] S Senn. Francis Galton and regression to the mean. *Significance*, 8(3):124–126, 2011.
- [546] J Spijker, R de Graaf, R V Bijl, A T F Beekman, J Ormel, and W A Nolen. Determinants of persistence of major depressive episodes in the general population. Results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). *J Affect Disord*, 81(3):231–40, 2004.
- [547] P Bower, E Kontopantelis, A J Sutton, T Kendrick, D A Richards, and S Gilbody et al. Influence of initial severity of depression on effectiveness of low intensity interventions: meta-analysis of individual patient data. *BMJ*, 346:f540, 2013.
- [548] W M McDonald, I H Richard, and M R DeLong. Prevalence, etiology, and treatment of depression in Parkinson’s disease. *Biol Psychiatry*, 54(3):363–375, 2003.
- [549] K S Kendler, C O Gardner, and C A Prescott. Toward a comprehensive developmental model for major depression in women. *Am J Psychiatry*, 159(7):1133–1145, 2002.
- [550] K S Kendler, C O Gardner, and C A Prescott. Toward a comprehensive developmental model for major depression in men. *Am J Psychiatry*, 163:115–124, 2006.
- [551] A J Rush, M H Trivedi, S R Wisniewski, A A Nierenberg, J W Stewart, and D Warden et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. *Am J Psychiatry*, 163(11):1905–17, nov 2006.
- [552] M H Trivedi, A J Rush, S R Wisniewski, A A Nierenberg, D Warden, L Ritz, G Norquist, R H Howland, B Lebowitz, P J McGrath, K Shores-Wilson, M M Biggs, G K Balasubramani, and M Fava. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. *Am J Psychiatry*, 163(1):28–40, 2006.
- [553] G I Spielmans, M I Berman, E Linardatos, N Z Rosenlicht, A Perry, and A C Tsai. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. *PLOS Med*, 10(3):e1001403, jan 2013.
- [554] P Cuijpers, M Sijbrandij, S L Koole, G Andersson, A T F Beekman, and C F Reynolds. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. *World Psychiatry*, 13(1):56–67, 2014.
- [555] M A Posternak and M Zimmerman. Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis. *Br J Psychiatry*, 190:287–92, 2007.

-
- [556] P Skapinakis, D M Caldwell, W Hollingworth, P Bryden, N A Fineberg, P Salkovskis, N J Welton, H Baxter, D Kessler, R Churchill, and G Lewis. Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. *Lancet Psychiatry*, 3(8):730–739, 2016.
- [557] A Tadic, D Wachtlin, M Berger, D F Braus, D van Calker, and N Dahmen et al. Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression-The EMC trial. *Eur Neuropsychopharmacol*, 26(4):705–716, 2016.
- [558] I Romera, V Pérez, J M Menchón, A Schacht, R Papen, D Neuhauser, M Abbar, P Svanborg, and I Gilaberte. Early switch strategy in patients with major depressive disorder. *J Clin Psychopharmacol*, 32(4):479–486, 2012.
- [559] M Zimmerman, H L Clark, M D Multach, E Walsh, L K Rosenstein, and D Gazarian. Have treatment studies of depression become even less generalizable? A review of the inclusion and exclusion criteria used in placebo-controlled antidepressant efficacy trials published during the past 20 years. *Mayo Clin Proc*, 90(9):1180–1186, 2015.
- [560] A N Goldstein-Piekarski, L M Williams, and K Humphreys. A trans-diagnostic review of anxiety disorder comorbidity and the impact of multiple exclusion criteria on studying clinical outcomes in anxiety disorders. *Translational Psychiatry*, 6(6):e847, 2016.
- [561] Yale University Open Data Access (YODA) Project, <http://yoda.yale.edu>.
- [562] Pfizer. Data access requests, http://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
- [563] Y A de Vries, A M Roest, and P de Jonge. The potential of individual patient data for research on antidepressant safety and efficacy. *Eur Neuropsychopharmacol*, 27(7):695–696, 2016.
- [564] J N Jureidini and J M Nardo. Inadequacy of remote desktop interface for independent reanalysis of data from drug trials. *BMJ*, 349:g4353, 2014.
- [565] National Institute of Mental Health. National Database for Clinical Trials related to Mental Illness (NDCT), <https://data-archive.nimh.nih.gov/ndct>.
- [566] E Karyotaki, H Riper, J Twisk, A Hoogendoorn, A Kleiboer, and A Mira et al. Efficacy of self-guided internet-based cognitive behavioral therapy in the treatment of depressive symptoms: a meta-analysis of individual participant data. *JAMA Psychiatry*, 74(4):351–359, 2017.
- [567] G James, D Witten, T Hastie, and R Tibshirani. *An introduction to statistical learning*. Springer, 6th edition, 2013.
- [568] J Flint and K S Kendler. The genetics of major depression. *Neuron*, 81(3):484–503, 2014.
- [569] G Parker. Classifying depression: Should paradigms lost be regained? *Am J Psychiatry*, 157(8):1195–1203, 2000.

